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ABSTRACT 
John Michael Dial 
 
Inhibition of the Cdh1-Dependent Anaphase Promoting Complex by Acm1 
(Under the direction of Dr. Christoph H. Borchers) 
 
Untimely progression through the cell cycle can lead to catastrophic and 
irreversible genetic anomalies.  Therefore, the cell cycle must be tightly controlled and 
proceed unidirectionally.  Cell cycle control is due in part to the targeted ubiquitin-
mediated proteolysis of regulatory proteins.  The anaphase-promoting complex (APC) is 
an essential E3 ubiquitin ligase responsible for catalyzing the proteolysis of regulatory 
proteins in the cell cycle.  Cdh1 is a co-activator of the APC aiding in the onset and 
maintenance of G1 phase, while phosphorylation of Cdh1 at the end of G1 phase by cyclin 
dependent kinases assists in the inactivation of APCCdh1.  Here, we suggest additional 
components are involved in the inactivation of APCCdh1 independent of Cdh1 
phosphorylation.  These components were identified as Acm1, Bmh1, and Bmh2 in 
complex with Cdh1.  Acm1 is cell cycle regulated and its levels are highest in S phase 
when APCCdh1 is inactive.  Complex formation is dependent on the presence of 
phosphorylated Acm1.  Acm1 alone is capable of inhibiting ubiquitination of Clb2 and 
Pds1 in vitro while overexpression of Acm1 rescues the lethality caused by 
overexpression of the constitutively active Cdh1 alanine phospho-mutant.  Acm1 
inhibition is specific to APCCdh1 as it does not inhibit APCCdc20 in vitro.  While partially 
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phosphorylated Cdh1 can still activate the APC, the addition of Acm1 decreases Clb2 
ubiquitination when using either phosphorylated or nonphosphorylated Cdh1. 
Cdh1 contains three consensus D-box regions (R-X-X-L) and one KEN box 
region.  Mutations of the 3rd D box and the KEN box of Cdh1 abolish its interaction with 
Acm1.  The same mutant is unable to inhibit APCCdh1 activity in vitro and in vivo. 
Although full length Acm1 does not appear to be ubiquitinated while serving as an APC 
inhibitor, truncations of both the N-terminus and C-terminus of Acm1 convert the protein 
to an APCCdh1 substrate.  We conclude Acm1 acts as a competitive inhibitor and blocks 
substrate binding to the Cdh1, thereby inactivating APCCdh1.  Together, these findings 
suggest a novel means of APCCdh1 regulation exists that is independent of Cdh1 
phosphorylation in yeast through inhibition by Acm1.  
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CHAPTER 1 
 
 
Introduction 
  2
Overview 
 
Defects in the regulation of the eukaryotic cell cycle are responsible for cell death, 
uncontrolled proliferation, and genetic anomalies (1-4). Therefore, progression of the cell 
cycle must be tightly controlled and proceed unidirectionally to prevent genetic 
catastrophe.  Cell cycle control is largely due to targeted proteolysis of regulatory 
proteins, specifically by ubiquitin-mediated proteolysis.  The anaphase-promoting 
complex (APC) is an essential E3 ubiquitin ligase responsible for catalyzing proteolysis 
of key regulatory proteins in the cell cycle.  The APC is closely regulated by 
phosphorylation and protein-protein interactions.  The APC has two co-activators in 
mitosis, Cdc20 and Cdh1, whose presence is necessary for APC activation and control 
substrate specificity.  Cdc20 and Cdh1 are also tightly regulated, modulating APC 
activity on additional levels.  The focus of this research examines the eukaryotic cell 
cycle and its regulation, specifically control of APCCdh1 activity by the negative regulator 
Acm1 in mitotic cells.  
 
The Eukaryotic Cell Cycle   
 
The main function of the cell cycle is to replicate the cell’s genome and allocate 
this information to two daughter cells.  These highly ordered events are described in four 
major phases, gap 1 (G1), synthesis (S), gap 2 (G2), and mitosis (M).  Gap 1 allows for 
cell growth in order for cells to double their mass of organelles and proteins that are 
required for DNA synthesis.  External and internal environmental factors are also closely 
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monitored during G1 phase for cells to certify all conditions are right for the major task of 
DNA synthesis in S phase (5).  The length of G1 can vary depending on extracellular 
conditions and signals.  If conditions are unfavorable, such as lack of proper nutrients for 
cell growth, cells will enter a specialized resting state known as G0.  Once conditions are 
favorable for cell growth, cells progress through G1 or G0 past a commitment point 
towards the end of G1 known as Start in yeast (5).  When cells reach Start they are then 
devoted to proceeding with DNA replication.  DNA replication or S phase involves the 
controlled synthesis of the chromosomal DNA.  Cells then enter G2 phase.  Much like G1, 
cells in G2 continue to monitor cellular conditions prior to entering mitosis.  G1, S phase, 
and G2 together make up interphase.  Mitosis, or M phase, follows G2 and is the process 
of dividing the replicated DNA from S phase into two daughter cells.  M phase is made 
up of six stages, including prophase, prometaphase, metaphase, anaphase, telophase, and 
cytokinesis.  Within M phase, the replicated DNA is packaged into sister chromatids 
which align at the center of the cell and microtubules connect the sister chromatids to 
spindle poles (5).  At the metaphase to anaphase transition, the microtubules shorten and 
the spindle poles move apart pulling the sister chromatids away from one another for 
incorporation into each daughter cell.  Untimely progression through this stage can be 
problematic.  For example, early onset of mitosis before complete DNA replication takes 
place or before microtubules are properly attached to sister chromatids can lead to 
aneuploidy (6).  Other crucial events include the exit from mitosis and the initiation of 
DNA replication at the G1/S phase transition.  Control of these important events in the 
life of a cell is largely controlled by cyclin-dependent kinases (CDKs), which consist of a 
catalytic protein kinase subunit and a regulatory cyclin subunit. 
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In Saccharomyces cerevisiae, a single CDK known as Cdc28 is able to regulate 
multiple cell cycle transitions in large by associating with different cyclins at specific 
times during the cell cycle.  In G1, Cdc28 requires three G1 cyclins, Cln1-3 while S phase 
is mediated by Clb5-6 and Clb1-4 govern mitosis (7).   
Phosphorylation of a variety of proteins by CDKs is required for cell cycle 
progression.  One example includes phosphorylation of the negative cell cycle regulator 
Sic1 (8).  Sic1 is an inhibitor of B-type cyclin (Clb)-CDK complexes preventing S phase 
entry and is stable until the G1/S phase transition when it is phosphorylated by G1 cyclin 
(Cln)-CDK activity triggering its proteolysis (9,10).   
CDK activity can be regulated in three different ways including phosphorylation 
of the kinase subunit, controlling protein levels through mRNA or protein degradation, 
and by activation or inactivation of CDK inhibitors (CKI) (7).  After each cell cycle 
phase is completed, down-regulation of the CDK activity responsible for the previous 
phase maintains tight control over the cell cycle transitions.  Just as early onset of mitosis 
before DNA replication is completed is disastrous for the cell, so are additional rounds of 
DNA replication before proper chromosome segregation.  Because of the great 
importance of proper cell cycle progression, eukaryotic cells have developed extensive 
mechanisms for CDK inactivation.  One important way cells govern CDK down-
regulation is through the destruction of cyclin subunits.  During both the G1/S phase and 
metaphase to anaphase transition, CDK activity is shutoff through the ubiquitin-mediated 
proteolysis of cyclins (11).  
 
Ubiquitin-mediated Proteolysis.   
  5
The driving force for forward progression and the primary mechanism by which 
each cell cycle stage changes is through ubiquitin-mediated proteolysis of regulatory 
proteins. Ubiquitin-mediated proteolysis is the most common way by which cells degrade 
proteins.  Ubiquitin is a small 8 kDa protein present in all eukaryotes.  Three distinct 
enzymatic activities occur to polyubiquitinate proteins resulting in their recognition and 
destruction by the proteasome.  First, the ubiquitin activating enzyme (E1) covalently 
binds the carboxyl terminus of the highly conserved ubiquitin protein via a thioester 
linkage.  The ubiquitin is then transferred to one of several ubiquitin-conjugating 
enzymes (E2).  The ubiquitin-protein ligase (E3) directs the transfer of the ubiquitin from 
the E2 to a lysine residue on a target protein substrate.  This process is repeated several 
more times so additional ubiquitin proteins are added to the first, creating a polyubiquitin 
chain that serves for recognition by the 26s proteasome (12).  The E3 enzyme is of great 
importance because it is responsible for directing ubiquitin conjugation to specific 
substrates at specific times.   
The list of cell cycle regulated substrates that are targeted for ubiquitin-mediated 
proteolysis is extensive.  In addition to cyclins, an important example is the precisely 
timed degradation of the mitotic inhibitor securin.  Securin is bound to a protease known 
as separase.  Upon degradation of securin, separase is freed to cleave cohesin, a protein 
which holds sister chromatids together in metaphase (13).  Once cohesin is cleaved, sister 
chromatids are allowed to separate and anaphase onset occurs.  Other notable examples 
of cell cycle regulated proteins include Sic1 in Saccharomyces cerevisiae and p27Kip1 in 
humans, both CDK inhibitors at the G1/S transition.  Most regulated proteolysis can be 
attributed to two ubiquitin ligases in the cell cycle.  One is the Skp1/Cul1/F-Box (SCF) 
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complex, required for the G1 to S phase transition and initiation of DNA replication (14).  
The other is the anaphase-promoting complex (APC), required for the metaphase to 
anaphase transition, exit from mitosis, and the onset and maintenance of G1 (15).   
 
The Skp1-Cul1-F-box protein complex and the Anaphase-Promoting Complex 
 
The SCF complex and the APC are members of the cullin based subfamily of E3 
ligases within the larger RING-finger-type E3 family.  The RING-finger-type E3s are one 
of four types of E3 ligases including HECT-type, U-box-type, and PHD-finger type all 
based on their specific structural motif.  Of these families, the RING-finger E3 is the 
largest.  The SCF complex consists of three main components, RBX1 (Ring-finger 
protein), CUL1 (scaffold protein), SKP1 (adaptor protein), and three interchangeable 
receptor proteins known as SKP2, FBW7, and β-TRCP (16).  The receptor proteins play 
a role in recognition of the E3 substrate and are thought to be involved in cell cycle 
control.     
The APC is a RING finger E3 ubiquitin ligase similar to the SCF.  It is a very 
large complex (1700 kDa) consisting of 13 subunits in yeast and 11 in humans (17-20). 
Its main function is suggested to bring the E2 and the substrate close enough together to 
allow for a direct transfer of ubiquitin.  The subunit APC2 (scaffold protein) consists of a 
cullin-homology region and is suggested to provide a platform for proper alignment of 
the E2 and substrate (21).  The subunit APC11 contains a Zn2+-binding motif referred to 
as the RING-H2 finger (22).  APC2 and APC11 are homologous to the functional core of 
the SCF ubiquitin ligases, and recent studies have shown they are essential for 
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ubiquitination activity (23,24).  Ubiquitin ligase activity of the APC has been shown to 
require the presence of one of two co-activator proteins in mitosis known as Cdc20 or 
Cdh1 (25-33). The co-activators interact with the APC at different times during the cell 
cycle with Cdc20 activating the APC from early to late M phase and Cdh1 from late M 
phase through G1 (27,29,34).  The co-activators Cdc20 and Cdh1 are characterized by a 
C-terminal WD-40 domain as well as a C-box and IR-tail (23,35,36).  The C-box and IR-
tail mediate the co-activator binding to the APC while the WD-40 domains recognize 
APC substrates through specific substrate regions called KEN boxes and D boxes 
(33,37,38).  Mutation of the WD-40 region of Cdh1 in complex with the APC disables 
binding to substrates (38).  The IR-tail of Cdh1 interacts with the TPR-domain protein 
Cdc27 on the APC complex (23,38).  Apc2 appears to interact with the C-box domain of 
Cdh1 either through Apc2 directly or indirectly by an Apc2 binding partner or Apc11 
(24).  Catalysis of the ubiquitination reactions may be enhanced by the proximity of Cdh1 
to the catalytic subunits Apc2 or Apc11 and the E2 enzyme (24). These findings support 
the role of the co-activators as necessary components for substrate recognition and APC 
activation.  
APC subunits have also been implicated in substrate recognition.  Reports have 
shown APC substrates bind directly to the APC but binding is dependent on the presence 
of Cdh1 or Cdc20 (36,37,39).  When the APC subunit Doc1 is deleted, APC can no 
longer bind to substrates and ubiquitinate them despite the APC binding to Cdh1 or 
Cdc20 (36,40).  Crystal structures of Doc1 have shown a globular domain with a surface 
predicted to interact with a ligand although the ligand is unknown (41).  Mutation of this 
region disables APC ubiquitination activity (42).  Therefore, evidence suggests Doc1 
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may play a role in substrate binding.   
The function of the numerous other APC subunits is less clear.  Swm1, Mnd2, 
Apc4, Apc9, and Cdc26 in S. cervisae do not share any significant homology with 
proteins of known function so their purpose is not known at this time.  Deletion of Cdc26 
has been shown to result in a decreased association of Apc9, Cdc16, and Cdc27 
suggesting Cdc26 stabilizes other APC subunits (43).  Other subunits may also play a 
role in stabilization of the APC complex.  Cdc27 association is diminished upon deleting 
APC9 (43).  Furthermore, deletion of SWM1 causes disassociation of Cdc16, Cdc26, 
Cdc27, and Apc9 from the APC (44).  However, questions concerning the mechanism of 
catalysis by the APC remain, including the function of the other numerous subunits and 
how and where substrates interact with the APC. 
The APC has essential functions within the cell cycle including mitotic 
progression, mitotic exit, and preparation for DNA synthesis that are dependent on the 
ability of APC to selectively recognize substrates at precise moments.  One important 
role APC plays in the cell cycle is in the initiation of cyclin B (Clb1,2 in budding yeast) 
proteolysis.  Destruction of B type cyclins begins in metaphase and is necessary for CDK 
inactivation and mitotic exit.  Once cyclin B is degraded, Cdk1 is rendered inactive 
allowing phosphatases to dephosphorylate Cdk1 substrates.  This leads to disassembly of 
the mitotic spindle, decondensation of chromosomes, reformation of the nuclear 
envelope, and formation of the cytokinetic furrow (11).  Low CDK activity during 
telophase and G1 is required for formation of pre-replicative complexes on replication 
origins where DNA polymerases initiate DNA synthesis.  B type cyclin degradation is 
mediated by APCCdc20 while cyclin B levels are kept at bay by APCCdh1 during G1.  
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Interestingly, lethality has been reported in cells with sic1∆ and cdh1∆ presumably 
because of the cell’s inability to inactivate cyclin B-CDK activity at mitotic exit (25,45).  
The B type cyclins Clb5 and Clb6 are also required for CDK activity and S phase entry 
but are not APC substrates.  Therefore, the APC maintains low CDK activity when pre-
replicative complexes are forming but allows CDK activation by Clb5 and Clb6 for DNA 
synthesis thereby allowing origins of replication to only fire once per cell cycle.   
As the name “anaphase-promoting complex” implies, another important role of 
the APC is in the advancement of metaphase to anaphase.  Securin, a co-chaperone and 
inhibitor of separase, is ubiquitinated by APCCdc20 triggering its proteolysis.  Separase is 
then allowed to cleave the Scc1 subunit of cohesin, a complex that holds sister 
chromatids together.  The cleavage of cohesin allows the disassociation of the sister 
chromatids thereby promoting anaphase.   
A large number of APC substrates have been reported (46).  The orchestrated 
activation of the APC for the timely degradation of substrates is of the utmost importance 
for the cell.  Therefore, highly evolved means of regulation are in place to control APC 
activity during the cell cycle window to mediate the ubiquitin-mediated destruction of 
these substrates.  
 
Regulating APC Activity 
 
The APC appears to be a very stable complex that is constitutively present 
throughout the cell cycle although its activity fluctuates (47,48).  One way of controlling 
APC activity is through phosphorylation of APC subunits.  For example, APC from 
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human mitotic extracts contain hyperphosphorylated APC1, CDC16, CDC23, and 
CDC27 (47).  During mitosis in budding yeast, the Cdc16, Cdc23, and Cdc27 subunits 
are also hyperphosphorylated (49).  Mutations in the CDK sites of these subunits resulted 
in reduced mitotic activity.  Kinases responsible for phosphorylation of the APC subunits 
have also been identified.  For instance, during mitosis CyclinB/Cdc2 (Clb2/Cdc28 in 
yeast) kinase activity is required for APC activation (49).  It is suggested that the family 
of Polo-like kinases phosphorylate APC subunits and aid in its activation (50).  In 
contrast to CyclinB/Cdc2 and Polo kinases, protein kinase A restricts APC activity by 
phosphorylating core subunits (50,51).  Other kinases involved in activation or 
inactivation of the APC are likely to exist.  
The APC catalyzes ubiquitin-mediated proteolysis of substrates at highly specific 
times within the cell cycle that allows for mitotic progression, exit from mitosis, and the 
onset and maintenance of G1.  APC substrate specificity must change throughout the cell 
cycle in order for these events to take place.  For example, the anaphase inhibitor Pds1 
(securin) is targeted for proteolysis by APC in metaphase, whereas several mitotic cyclins 
are degraded after anaphase (13,52).  Other substrates such as the S-phase promoting 
factor Dbf4 are targeted for destruction in G1 (53).  Substrate specificity is regulated in 
large by the recruitment of co-activator proteins that associate with particular substrates 
throughout the cell cycle.  The co-activators Cdc20 and Cdh1 function to bind specific 
substrates and are subsequently recruited to the APC where the substrate is poly-
ubiquitinated for degradation by the proteasome.   
The co-activators interact with specific substrates at specific times so they 
themselves must be regulated.  Phosphorylation of Cdc20 and Cdh1 is an important 
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control mechanism for both APCCdc20 and APCCdh1 complexes.  In some instances, 
phosphorylation of Cdc20 appears to be necessary for activity of APCCdc20 but not in 
others (28,54).  Although Cdc20 is transcribed and translated during S phase and G2, it 
can only activate the APC in mitosis when certain APC subunits are phosphorylated 
(49,55,56).  Phosphorylation of Cdh1 by the cyclin-dependent kinase (CDK), Clb5-
Cdc28, inhibits its interaction with the APC (28,54,57).  Cdh1 remains 
hyperphosphorylated throughout S, G2, and M phase until a drop in CDK activity is 
triggered by Cdc14 phosphatase (34,58).  Therefore, APCCdc20 is active during early 
mitosis, whereas APCCdh1 can only become activated after APCCdc20 decreases CDK 
activity through cyclin destruction allowing dephosphorylation of Cdh1 by Cdc14 
phosphatase and subsequent activation of APCCdh1.  APCCdc20 is then inactivated through 
APCCdh1 mediated proteolysis of Cdc20 (34,59,60).  APCCdh1 maintains G1 phase until it 
is inactivated at the G1/S transition by S phase CDKs (34).  The main S phase cyclin that 
activates CDKs in budding yeast is Clb5.  Clb5 is an APCCdc20 substrate whose levels are 
low during mitosis (61).  Once APCCdc20 is inactivated, Clb5 accumulates and activates 
Cdc28 allowing the CDK to phosphorylate Cdh1, preventing its interaction with the APC.    
While phospho-regulation of co-activators plays an important role in controlling 
APC activity, interactions between the co-activators and other proteins are also important 
for their regulation.  In vertebrates, a second APCCdh1 inhibition mechanism is in place.  
The early mitotic inhibitor-1 (Emi1) is expressed at the G1/S phase transition and 
competitively inhibits the binding of substrates to APCCdh1 by acting as a pseudosubstrate 
(62,63). The spindle checkpoint proteins Mad2p and Mad3p/BubR1p bind and inhibit 
Cdc20 in a substrate specific manner to arrest the metaphase to anaphase transition until 
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all chromosomes have properly attached to the mitotic spindle (64-68).  Emi1 has also 
been shown to inhibit APCCdc20 as a proposed early mitotic inhibitor before the activation 
of the spindle assembly checkpoint (69,70).  The tumor suppressor protein RASSF1A 
regulates the timing of mitotic progression by inhibiting the APCCdc20 complex (71).  Still 
others, such as the S-phase checkpoint proteins Mec1p and Rad53 are shown to repress 
Cdc20 accumulation in S-phase to prevent premature mitotic onset (72).  Relocalization 
of Cdh1 from the nucleus to the cytoplasm by the exportin Msn5 has been shown to occur 
at the end of G1 before S phase and remains in the cytoplasm between S phase and the 
end of mitosis presumably as a redundant mechanism ensuring efficient inactivation (73).   
Clearly, multiple inhibitory mechanisms are in place to control APC activity because it is 
crucial to the cell cycle proceeding unidirectionally.   
The goal of this research project was to identify new regulatory mechanisms of 
the anaphase promoting complex through the APC co-activator Cdh1.  With the advent of 
highly sensitive tools for analyzing proteins and peptides such as mass spectrometry, we 
have the capability to identify potentially novel interacting proteins of the anaphase 
promoting complex.  Before the inception of this work illustrated in the following 
chapters, no protein inhibitors of APCCdh1 activity had been identified in yeast. 
 
The APC and cancer 
 
Deregulation of cell cycle control is fundamental to cancers.  Hence, studying 
APC regulation is of great clinical importance.  Although the APC is not linked to cancer 
as notably as the SCF, it can be expected that deregulation of either Cdc20 or Cdh1 could 
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have devastating effects on cell proliferation.  Cdc20 overexpression has been linked to 
pancreatic cancer while its upregulation has been shown in lung and gastric cancer 
patients (74,75).  The spindle assembly checkpoint proteins Mapd2p, Mad3p, and BubR1 
which inhibit APCCdc20 activity, prevent precocious segregation of chromosomes leading 
to aneuploidy, a common form of genetic instability found in cancers (76).  Securin, an 
APCCdc20 substrate is commonly overexpressed in human tumors (77,78).  Cdh1 
expression is reduced during the malignant progression of a murine B-lymphoma cell 
line, while the overexpression of Cdh1 suppressed tumor formation (79).  Mutations in 
APC subunits have also been linked to cancer.  Mutations in Apc6 and Apc8 have been 
described in human colon cancer cells (80).  The mutation of Apc8 leads to the 
misregulation of cyclin B levels whose overexpression leads to genomic instability found 
in colon cancer (80).  Other APC substrates have been tied to cancer including the 
kinases Plk1 and Aurora A.  Plk1 controls mitotic entry and cytokinesis and is 
overexpressed in several tumor types (81).  Levels of Aurora A, whose role involves 
aiding centrosome duplication and separation as well as spindle assembly, are increased 
in bladder, pancreatic, and ovarian cancers (82-84).  Plk1 and Aurora A levels are both 
mediated by APCCdh1 further suggesting misregulation of APC can lead to tumorigenesis.  
 Our knowledge of the mechanisms of APC regulation is steadily increasing, 
leading to the discovery of what roles these mechanisms may play in the development of 
cancer.  The ultimate goal of studying E3 ligases like the APC in cell cycle control is to 
develop cancer therapeutic treatments that specifically target these enzymes.  Some 
progress has been made in this arena including a small molecule known as 2-
methoxyestradiol (2ME2).  In collaboration with Nancy DeMore, we have shown 2ME2 
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to inhibit APC activity through the regulation of genes involved in the spindle assembly 
checkpoint, resulting in a G2/M phase arrest (85).  Currently, 2ME2 is in phase I/II 
clinical trials for breast cancer treatment. 
  
Summary 
 
Proper control of the eukaryotic cell cycle is crucial to preventing genetic 
catastrophes in the cell.  The anaphase-promoting complex is an important cell cycle 
regulating E3 ubiquitin ligase aiding in mitotic progression and a stable G1 phase.  
Defects in APC regulation have detrimental consequences leading to tumorigenesis.  Our 
research focuses on the regulation of the APC co-activator Cdh1 during the cell cycle.  
Specifically, this work concentrates on the discovery and characterization of a novel 
APCCdh1 inhibitor in budding yeast known as Acm1.  We discovered an uncharacterized 
protein known as Acm1 in a proteomic screen of Cdh1 associated proteins.  Along with 
Acm1, the 14-3-3 proteins Bmh1 and Bmh2 were identified.  Acm1, Bmh1, and Bmh2 
form a complex with Cdh1 although Acm1 alone is sufficient for APCCdh1 inhibition.  
The results of this work have determined Acm1 is an APCCdh1 specific inhibitor, acting 
independently of Cdh1 phosphorylation as an overlapping inhibitory mechanism.  Acm1 
mimicks an APC substrate and inhibits APCCdh1 activity by blocking substrate binding to 
Cdh1.  The results of this work provide further insight into the complex nature of APC 
regulation.  The discovery and characterization of this novel inhibitory mechanism is 
outlined in the following chapters. 
    
CHAPTER 2 
 
 
 
Inhibition of APCCdh1 activity by Cdh1/Acm1/Bmh1 ternary complex formation 
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Overview 
 
The anaphase-promoting complex (APC) is an essential E3 ubiquitin ligase 
responsible for catalyzing proteolysis of key regulatory proteins in the cell cycle.  Cdh1 is 
a co-activator of the APC aiding in the onset and maintenance of G1 phase, while 
phosphorylation of Cdh1 at the end of G1 phase by cyclin dependent kinases assists in the 
inactivation of APCCdh1.  Here, we suggest additional components are involved in the 
inactivation of APCCdh1 independent of Cdh1 phosphorylation.  We have identified 
proteins known as Acm1 and Bmh1 that bind and form a ternary complex with Cdh1.  
The presence of phosphorylated Acm1 is critical for the ternary complex formation, and 
Acm1 is predominantly expressed in S phase when APCCdh1 is inactive.  The assembly of 
the ternary complex inhibits ubiquitination of Clb2 in vitro by blocking Cdh1’s 
interaction with Clb2.  In vivo, lethality caused by overexpression of constitutively active 
Cdh1 is rescued by overexpression of Acm1.  Partially phosphorylated Cdh1 in the 
absence of ACM1 still binds to and activates the APC.  However, the addition of Acm1 
decreases Clb2 ubiquitination when using either phosphorylated or nonphosphorylated 
Cdh1.  Taken together, our results suggest an additional inactivation mechanism exists 
for APCCdh1 that is independent of Cdh1 phosphorylation.  
 
Introduction 
 
The eukaryotic cell cycle is largely controlled by targeted proteolysis of 
regulatory proteins, specifically through ubiquitin-mediated proteolysis (1-4). The 
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anaphase-promoting complex (APC) is an essential E3 ubiquitin ligase responsible for 
catalyzing proteolysis of key regulatory proteins in the cell cycle.  Substrate specificity of 
the APC is attributed to co-activator proteins that associate with particular substrates 
throughout the cell cycle (25,29,35).  The co-activators Cdc20 and Cdh1 are thought to 
aid in the recruitment of particular substrates through substrate binding independent of 
the APC or in assemblies known as APCCdc20 or APCCdh1 (38,39,86). The APC poly-
ubiquitinates substrates, marking them for degradation by the proteasome (32,35).  
Ubiquitin ligase activity of the APC has been shown to require the presence of Cdc20 or 
Cdh1 (27-29,32,33).  Co-activators interact with the APC at specific times during the cell 
cycle, with Cdc20 activating the APC from early to late M phase and Cdh1 activating the 
APC from late M phase through G1 (27,29,34).   
Phosphorylation of Cdh1 has been demonstrated as an important control 
mechanism for the APCCdh1
 
complex (57).  Phosphorylation of Cdh1 is cell cycle 
dependent and is considered to be the main regulatory mechanism by which APCCdh1 is 
inactivated.  Cdh1 is phosphorylated in S phase, G2, and mitosis and dephosphorylated in 
G1 (57).  The phosphorylation of Cdh1 corresponds to high levels of the cyclin-dependent 
kinase (CDK) activity. When the CDK consensus phosphorylation sites within Cdh1 
from budding yeast were mutated to alanine, Cdh1 activated the APC constitutively, 
failing to accumulate mitotic cyclins (57).  Cdh1 is phosphorylated at the G1/S phase 
transition by G1 and S phase cyclins that activate the CDK in budding yeast, Cdc28.  
Cdh1 remains hyperphosphorylated until late in mitosis when Cdc14 phosphatase is 
activated allowing Cdh1 to reactivate the APC (34,58).  In S and M phases, Cdh1 failed 
to associate with the APC in Cdh1 co-immunoprecipitations (57).  Additionally, in vitro 
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phosphorylation of recombinant Cdh1 by CDKs is sufficient for inactivation of the APC 
(87).   
Protein-protein interactions have also been shown to be important in the 
regulation of Cdh1 (88,89).  In higher eukaryotes, Emi1 and Mad2B have been shown to 
inhibit Cdh1 through protein-protein interactions (88,89).  Although the function of 
Mad2B is unclear, Emi1 is reported to inhibit substrate binding to Cdh1.  However, 
similar inhibitors in yeast have not yet been identified.   
In order to discover potentially novel Cdh1 interacting proteins, we performed a 
proteomic screen of Cdh1 immunoprecipitations in budding yeast.  In the process, we 
identified a multi-protein complex which forms with Cdh1, consisting of a previously 
uncharacterized protein Acm1 (YPL267W) and two members of the 14-3-3 protein 
family known as Bmh1 and Bmh2. The expression of Acm1 is cell cycle dependent, and 
Acm1 is necessary for complex formation with Cdh1 and Bmh1.  Formation of the 
complex, which we refer to as the CAB complex or Cdh1/Acm1/Bmh1 complex, is 
restricted to the cell cycle window in which Acm1 is expressed.  Without Acm1, Clb2 
levels in vivo appear lower when compared to cells containing Acm1 under certain 
growth conditions. Complex formation inhibits APCCdh1 activity in vitro, and lethality 
caused by overexpression of constitutively active Cdh1 is rescued by Acm1 
overexpression.  The CAB complex functions to block substrate binding with the co-
activator.  Partially phosphorylated Cdh1 binds and activates the APC in the absence of 
Acm1.  Lastly, we have shown the ability of Acm1 and Bmh1 to inhibit APCCdh1 despite 
the Cdh1 phosphorylation state.  Taken together, our data suggests the existence of an 
additional inactivation mechanism of APCCdh1 independent of Cdh1 phosphorylation.   
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Experimental Procedures 
 
Cloning.  Cloning for p415ADH-FLAGCdh1 and pNC219-FLAGCdh1m9 have been 
described (90).  The resulting centromeric plasmid, p415ADH-FLAGCdh1, constitutively 
expresses 3xFLAG-CDH1 from the ADH promoter.  pNC219-FLAGCdh1m9 expresses 
the 3xFLAG-CDH1 phosphomutant with 9 of 11 CDK sites mutated to alanine from the 
GAL promoter.  The plasmids pHLP117 expressing 3HA-Acm1 from its natural 
promoter, pHLP107 expressing FLAG-Acm1 from the ADH promoter, and pHLP106 
expressing FLAG-Acm1 from the GAL1 promoter were gifts from M. Hall.  The 
plasmids pRSETClb2, pET28-His6-Cdh1, and  pET28-His6-Ubc4 were gifts from D. 
Barford (36).  BMH1 and CLB2  were amplified by PCR from yeast genomic DNA and 
cloned into pGEX-4T-1 at the BamH1 and Xho1 sites yielding a GST tag on the amino 
terminus of Bmh1 and Clb2 for overexpression in E. coli.  All PCR generated constructs 
were confirmed by DNA sequencing. 
 
Strains and Media.  Yeast strains are described in Table I.  YPD (20g/L peptone 
[Fisher], 10g/L yeast extract [Bacto], 20g/L dextrose [MP Biomedicals]); YP (20 g/L 
peptone, 10 g/L yeast extract); synthetic medium (6.7 g/L yeast nitrogen base lacking 
amino acids [Difco], 20 g/L dextrose or 20 g/L raffinose, appropriate amino acid dropout 
mix [Q-Biogene]).   
Cell Cycle Arrest.  For G1 arrest in bar1 cells, α-factor peptide is added directly to the 
cultures during mid-log phase growth at 50 µg/L.  BAR1 cells require 3 µg/ml α-factor 
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peptide for an effective G1 arrest.  Arresting in S phase requires the addition of 10 mg/ml 
hydroxyurea (Sigma).  M phase arrests are carried out by the addition of 15 mg/ml 
nocodazole (Sigma).  This lab has acquired a cdc15-2 yeast strain that allows cell cycle 
arrest in telophase induced by temperature shift from 25° C to 37° C. Cell cycle arrests 
are monitored by phase-contrast microscopy until >90% of the cells have achieved the 
desired morphology.  
 
Cdh1 Purification.  Yeast cells were grown asynchronously to OD600=1 and lysed in 1 
volume of APC-C lysis buffer (25mM HEPES-NaOH pH 7.5, 400mM NaCl, 10% 
glycerol, 0.1% Triton X-100, 0.1mM dithothreitol, 0.5mM PMSF, and complete protease 
inhibitor cocktail (Roche)) by vortexing for 45 min. at 4° C in 1.7 ml microcentrifuge 
tubes containing 0.5 ml 0.5 mm glass beads. Cell lysate was cleared by centrifugation at 
16,000 x g for 15 min.  Soluble extracts were pooled and cleared a second time at 5000 
rpm for 5 min.  Extracts were incubated with anti-FLAG M2 antibody-coupled resin 
(Sigma) for 1.5 hrs. at 4° C.  Bound Cdh1 was washed extensively with APC-C buffer 
(25mM HEPES-NaOH pH 7.5, 400mM NaCl, 10% glycerol, 0.1% Triton X-100, 0.1mM 
dithothreitol, 0.5mM PMSF) and eluted 2X with FLAG peptide (250 µg/ml) in APC-C 
buffer.   
 
APC Purification.  Yeast cells were grown, lysed, and lysates cleared in the same 
manner as Cdh1.  Extracts from YNL172W-TAP were incubated with Calmodulin 
affinity resin (Stratagene) for 1.5 hrs. at 4° C in APC-C buffer containing 1mM CaCl2.  2 
L of cells from YKA156 were grown to OD600=0.5 at 25° C and temperature shifted to 
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37° C for 2 hours.  Extracts from YKA156 were incubated with EZView anti-FLAG M2 
antibody-coupled resin (Sigma) for 1.5 hrs. at 4° C, washed extensively with APC-C 
buffer and eluted 2X with FLAG peptide (250 µg/ml) in low salt APC-C buffer (25mM 
HEPES-NaOH pH 7.5, 150mM NaCl, 10% glycerol, 0.1% Triton X-100, 0.1mM 
dithothreitol).   
 
Acm1 Purification.  Yeast cells were grown, lysed, and lysates were cleared in the same 
manner as Cdh1 purifications.  Extracts from YPL267W-TAP were incubated with 
Calmodulin affinity resin (Stratagene) for 1.5 hrs. at 4° C in APC-C buffer containing 
1mM CaCl2.  Acm1 bound to beads were used in binding assays.  Acm1 used in the 
ubiquitination assay and Clb2 binding assay was eluted with TAP elution buffer (40 mM 
Tris pH 7.5, 0.6mM DTT, 2.5 mM EDTA) for 30 minutes at room temperature while 
shaking at 700 rpm.  MgCl2 was added to the elution buffer at a final concentration of 15 
mM.  FLAG-Acm1 used in the ubiquitination assay and binding assays was purified in 
the same manner as APC. 
 
Bmh1/Clb2 Purification.   Overnight cultures of E. coli harboring BMH1 or CLB2 in the 
pGEX-4T-1 plasmid were grown and used to inoculate 1L of 2XYT (16g/L tryptone, 10 
g/L yeast extract, 5 g/L NaCl) containing 100 µg/ml ampicillin.  Cultures were grown for 
8 hours at 37° C, temperature shifted to 23° C and IPTG added (100 µM final).  Cells 
were grown overnight and harvested by centrifugation.  Cell pellet was resuspended in 
1X PBS 0.5 M NaCl keeping suspension on ice.  Cells were lysed 3X using sonication for 
20 sec. intervals with a 40 sec. pause.  Lysates were cleared by centrifugation at 4° C and 
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25,000 rpm for 30 min.  Cleared lysates were incubated with 100 µl washed GSH beads 
(Amersham glutathione sepharose 4B) for 10 min.  Beads and lysate were pipetted and 
transferred to Bio Rad micro columns.  Beads were washed with 5 column volumes of 1X 
PBS 0.5 M NaCl.  Bound protein was used on the GSH beads for binding assays.  Bmh1 
used in the ubiquitination assay was treated with biotinylated thrombin (Novagen) to 
cleave the GST tag.  Sample was treated with streptavidin agarose to remove thrombin.  
Buffer was exchanged with 40 mM Tris pH 7.5, 0.6 mM DTT, 10 mM MgCl2 using 
microcon filters with a 10 kDa cutoff (Millipore).      
 
In Vitro Binding Assays.  Compact reaction columns (USB) were used for all binding 
assays.  Protein used as bait was immobilized on affinity beads and washed in the 
reaction column.  Protein used as prey was added to each column and allowed to incubate 
for times noted at 4° C under rotation.  Columns were washed with five column volumes 
of APC-C lysis buffer and eluted in 1X NuPAGE LDS sample buffer (Invitrogen) unless 
the immobilized protein used the TAP tag.  In TAP purifications, APC-C buffer 
containing 1 mM CaCl2 was used for washes.  Five percent of each reaction was loaded 
on the gel.     
 
Ubiquitination Assay.  Ubiquitination assays were carried out as described by D. 
Barford (36).  The substrate Clb2 (pRSETClb2), the co-activator Cdh1 (pET28-His6-
Cdh1), and the E2 Ubc4 (pET28-His6-Ubc4) were prepared using the TNT T7 Quick 
coupled in vitro transcription/translation kit (Promega) unless otherwise noted.  APC 
(YKA156) and Acm1 were purified from budding yeast (see APC and Acm1 
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purification) while Bmh1 was expressed and purified from E. coli (see Bmh1 
purification).  APC used in each reaction was 1/50 of the elution from 2 L of cells.  Clb2 
was radiolabeled with S35 methionine (Perkin Elmer).   Reactions were run on a 4-12% 
Bis-Tris NuPAGE gel (Invitrogen), dried, and imaged using Hyperfilm (Amersham 
Biosciences). 
 
Flow cytometry.  Cells were prepared as described previously (91).  DNA content was 
measured on a FACScan instrument and ModFit LT software (Verity Software House, 
Inc.) used to calculate percentages of G1, S, and G2/M cells present. 
 
Protein Identification and Mass spectrometry.  Elutions from Cdh1 purifications were 
acetone precipitated, reconstituted in 1X LDS sample buffer containing 100mM DTT and 
separated on a 4-12% Bis-Tris NuPAGE gel (Invitrogen). Gels were stained with 
Coomassie blue or silver. Protein bands were excised, destained and incubated with 
trypsin. After digestion, samples were frozen, lyophilized and resuspended in a small 
volume of 50% methanol/0.1% formic acid. Peptide masses were analyzed on a MALDI-
TOF/TOF mass spectrometer (Applied Biosystems) and proteins identified using the 
MASCOT search engine (Matrix Science). Samples which needed further analysis were 
analyzed on a nano-ESI Q-TOF (Micromass) mass spectrometer. 
 
Gel Filtration.  FLAG immunoprecipitations were prepared from S phase arrested cells 
in APC-C buffer.  The samples were fractionated on a Superdex 200 HR 10/30 gel 
filtration column with extraction buffer on an AKTA Explorer system (Amersham 
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Biosciences) at 0.4 ml/min.  Fractions were collected in 0.5 ml increments and each 
fraction acetone precipitated. Proteins were resolved by SDS-PAGE and detected by 
immunoblotting with an α-FLAG antibody. 
  
Results 
 
Acm1 and Bmh1 associate with Cdh1 in vivo and in vitro and form a ternary 
complex.  To identify potential interacting proteins of Cdh1, we used a targeted 
proteomic approach consisting of immunoprecipitations with genomically FLAG tagged 
Cdh1 followed by mass spectrometric analysis.  We discovered three proteins known as 
Acm1, Bmh1, and Bmh2 in budding yeast which stably interact with Cdh1 under high 
salt wash conditions (Fig. 1.1A).  The untagged parent strain was used as a control. C-
terminal Cdh1 fragments were also identified by mass spectrometry.  Interestingly, we 
did not identify any other specific proteins in the Cdh1 immunoprecipitation presumably 
due to the high salt wash conditions which disrupt all but the most stable protein 
complexes.  Gel filtration analysis of the complex showed co-elution of Cdh1 and Acm1 
in a stoichiometric interaction (data not shown).  Acm1 (APCCdh1 modulator 1) is a 
previously uncharacterized protein with no known function although it was originally 
identified as a potential CDK substrate (92).  However, as members of the 14-3-3 family 
of proteins, Bmh1 and Bmh2 have been associated with a variety of cellular processes 
and have been defined as phosphoserine-binding proteins (93,94).   We believe two 
possibilities for these interactions exist, either as potential APCCdh1 substrates or as 
regulators of Cdh1.   
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To confirm the specificity of the interactions between Cdh1, Acm1, and Bmh1, 
we used in vitro binding assays.  FLAG tagged Cdh1 and TAP tagged Acm1 were 
purified from yeast while recombinant Bmh1 was expressed in E. coli.  GST-Bmh1 was 
immobilized on GSH beads and incubated with Cdh1-FLAG.  GST bound to GSH beads 
was used as a control.  Acm1-TAP was immobilized on calmodulin beads and incubated 
with Cdh1-FLAG.  Empty calmodulin beads served as a control.  Likewise, Acm1-TAP 
was incubated with GST-Bmh1. We observed a stable interaction between Bmh1/Cdh1, 
Acm1/Cdh1, and Acm1/Bmh1 under high-salt wash conditions (Fig. 1.1B).  In order to 
see if any one component of the CAB complex was necessary for complex formation, we 
performed immunoprecipitations from strains deleted for components of the complex.  
We expressed N-terminally FLAG tagged Cdh1 in WT, acm1∆, bmh1∆, and bmh2∆ 
strains and immunopurified with anti-FLAG antibody followed by gel electrophoresis 
and mass spectrometric analysis.  Gel slices for each region where Cdh1, Acm1, Bmh1, 
and Bmh2 migrate were analyzed.  Bmh1 and Bmh2 cannot be detected in the absence of 
Acm1.  In the bmh1∆ strain, Acm1 and Bmh2 still associated with Cdh1.  Likewise, 
Acm1 and Bmh1 still associated with Cdh1 in the bmh2∆ strain (Fig. 1.1C).  
Additionally, we incubated purified FLAG-Cdh1 from either wild type or acm1∆ cells 
with immobilized GST-Bmh1 in an in vitro binding assay.  Without Acm1, Cdh1 does 
not bind Bmh1 (Fig. 1.1D, lane 6).  The Bmh1/Cdh1 binding in Fig. 1.1B is attributed to 
the presence of Acm1 which co-purifies with Cdh1. Together these findings illustrate the 
dependence of the CAB complex formation on Acm1 as well as a possible redundancy 
between Bmh1 and Bmh2.   
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Acm1 is expressed in S phase and has an effect on cell cycle progression.  Because 
Cdh1 activates the APC in a cell cycle dependent manner, the interaction with Acm1 and 
the 14-3-3 proteins could also fluctuate throughout the cell cycle.  In order to determine 
whether these proteins were regulated in a cell cycle dependent manner, Acm1-TAP and 
Bmh1-TAP protein levels were analyzed in cell lysates from G1, S, and M phase arrested 
cells.  Acm1 levels were found to be significantly higher in S phase over the other cell 
cycle phases, while Bmh1 levels remain constant in each cell cycle stage (Fig. 1.2A).  
This finding is in agreement with the Acm1 mRNA expression pattern throughout the cell 
cycle (95).  Analysis of Acm1 mRNA expression levels from the Saccharomyces 
Genome Database revealed the closest pattern of gene expression to Acm1 is observed 
for Clb5 (95).  Clb5-Cdc28 is believed to be the primary cyclin-CDK complex 
responsible for phosphorylation of Cdh1 during S phase, although other G1 cyclin-CDK 
complexes are also involved (34,96,97).  Acm1 protein levels are highest in S phase 
when Cdh1 is phosphorylated and APCCdh1 becomes inactivated.  This observation 
suggested an involvement of Acm1 in phosphorylation-mediated regulation of APCCdh1 
during S phase. 
We did not expect the deletion of ACM1 to induce large perturbations in the cell 
cycle.  According to the Saccharomyces Genome Database, cells with ACM1 
systematically deleted were viable (98). Indeed, acm1∆ cells grow at normal rate when 
compared to WT cells.  In order to see if deleting ACM1 had any effect within a single 
cell cycle, cells from acm1∆ and wild type strains were synchronized in S phase with 
hydroxyurea, released and analyzed by flow cytometry for DNA content in 20 minute 
intervals (Fig. 1.2B).  Interestingly, FACS analysis of acm1∆ cells showed an increase 
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(14%) in the S phase cell population in comparison to wild type cells at 80 minutes after 
release.  This effect was reproducible but to slightly varying degrees (data not shown).  
Additionally, the acm1∆ strain resynchronized with WT cells in M phase.  The effect in S 
phase progression in acm1∆ cells suggests Acm1 may play a role in cell cycle 
progression throughout S phase.  If the CAB complex does play a role in APCCdh1 
regulation, one would expect a difference in APCCdh1 substrate levels in cells lacking 
Acm1.  In order to test whether APCCdh1 substrates are affected in acm1∆ cells, we 
performed a G1 block-release experiment in cells containing Acm1 compared to cells 
void of Acm1 and examined levels of the known APCCdh1 substrate Clb2.  Interestingly, 
we found a slight decrease in Clb2 levels in early time points in the absence of Acm1 
under certain growth conditions (Fig. 1.2C).  The cycling pattern of Clb2 corresponds to 
that of Acm1 although Acm1 increases to its maximum slightly before Clb2 reaches its 
highest level.  An increased level of APCCdh1 activity in the strain lacking Acm1 could 
explain this difference in Clb2 levels between the two strains.  However, the effects in the 
cell cycle are slight, so CAB complex formation may exist as an overlapping inhibitory 
mechanism in addition to phosphorylation for APCCdh1.   
 
CAB complex formation inhibits APCCdh1 mediated ubiquitination of Clb2.  Since 
Acm1 was predominantly expressed in S phase when APCCdh1 activity is inhibited and 
cells lacking Acm1 exhibited a difference in Clb2 levels, we investigated whether the 
CAB complex formation affected APCCdh1 activity directly.  To demonstrate a possible 
inhibitory effect of Acm1 and Bmh1 on APC activity, an in vitro ubiquitination assay 
was used to measure ubiquitination of the substrate Clb2 (Fig. 1.3A).  APC and TAP 
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tagged Acm1 were purified from yeast while Ubc4 (E2), Cdh1, and S35-labeled Clb2 
were expressed in vitro and incubated together for the assay.  The degree of substrate 
ubiquitination was measured by phosphorimage analysis of S35-labeled Clb2.  With 
Bmh1 levels held constant, increasing concentrations of Acm1-TAP resulted in a dose-
dependent inhibition of Clb2 ubiquitination (lanes 3, 4, and 5).  A mock purification from 
acm1∆ cells was used to rule out buffer or non-specific protein effects on APCCdh1 
activity and illustrates Clb2 ubiquitination levels without any inhibition (lane 6).  In order 
to quantify Acm1 inhibition relative to APC and Cdh1 levels, we used yeast purified 
FLAG-tagged APC, Cdh1, and Acm1 (Fig. 1.3B).  Acm1 appears to inhibit APC activity 
at substoichiometric levels (Fig. 1.3B, lanes 5-7 and 10-12) although we have observed 
stoichiometric binding from our gel filtration data.  We attribute this result to the 
presence of a certain percentage of inactive Cdh1 in the preparation.  No inhibitory effect 
on Clb2 ubiquitination was observed upon the addition of Bmh1 alone (Fig. 1.3B, lane 4).  
This is not surprising due to the requirement of Acm1 for the Bmh1/Cdh1 interaction.  
From our in vitro ubiquitination assay results, we conclude Acm1 and Bmh1 have an 
inhibitory effect on APCCdh1 ubiquitin ligase activity.     
 To investigate whether Acm1 inhibits APCCdh1 activity in vivo, we co-expressed 
Acm1 and the constitutively active Cdh1 mutant containing 9 of the 11 CDK 
phosphorylation sites mutated to alanine.   It has been previously shown that Cdh1 
phosphomutants mimicking non-phosphorylated Cdh1 were unable to accumulate Clb2 
and Clb3, to form mitotic spindles, and undergo cytokinesis (57). We found 
overexpression of Acm1 rescues the lethality caused by overexpression of the Cdh1 
phosphomutant (Fig. 1.3C).  From this experiment, we concluded the CAB complex 
  29
formation suppresses APCCdh1 activity as an overlapping regulatory mechanism in the 
absence of complete CDK phosphorylation.  This mechanism exists in addition to Cdh1 
phosphorylation which has clearly been shown to also inhibit APCCdh1 activity.  CAB 
complex formation may function then to inhibit APCCdh1 regardless of the 
phosphorylation status of Cdh1.   
Our next question was how CAB complex formation inhibited APCCdh1 activity.  
Enzymatic activity of APCCdh1 is mediated by the interaction between Cdh1, APC, and 
the substrate.  Therefore, we hypothesized the complex either blocked APC binding to 
Cdh1 or blocked Cdh1 binding to Clb2.  To determine whether Acm1 and Bmh1 were 
inhibiting APCCdh1 activity by blocking the APC/Cdh1 interaction or by blocking 
substrate binding to Cdh1, we performed binding assays between Cdh1-APC and Cdh1-
Clb2 with or without the presence of the other complex components (Fig. 1.3D, 1.3E).  
Bacterially expressed GST-Clb2 was incubated with FLAG-Cdh1 from acm1∆ cells after 
Cdh1 was pre-incubated with varying levels of Acm1 in an in vitro binding assay.  In the 
second in vitro binding assay, N-terminally tagged FLAG-Cdh1 was purified from WT 
and acm1∆ cells and incubated with APC via Apc1-TAP.  Although, no difference in 
Cdh1 binding to the APC could be seen in the presence or absence of Acm1 (Fig. 1.3E, 
compare lane 13 and 17), Cdh1 binding to Clb2 decreased in a dose dependent manner 
with increasing levels of Acm1 (Fig. 1.3D, lanes 5-8).  This observation suggests Acm1 
disrupts the interaction between the substrate and Cdh1 which may explain how CAB 
complex formation inhibits APCCdh1 activity.    
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Formation of the complex is phosphorylation dependent.  Current data supports the 
important role Cdh1 phosphorylation plays in the inactivation of APCCdh1 activity.  
Therefore, we hypothesized phosphorylation had some involvement with the interaction 
between Cdh1, Acm1, and Bmh1.  To determine what role phosphorylation plays in the 
complex, we employed an in vitro binding assay between Bmh1 and Cdh1 with and 
without phosphatase treatment of Cdh1 (Fig. 1.4A).  Cdh1-FLAG was purified from WT 
cells, treated with λ-phosphatase, and incubated with immobilized GST-Bmh1 in an in 
vitro binding assay.  Cdh1-FLAG treated with phosphatase buffer but without λ-
phosphatase was used as a control.  A shift in Cdh1 due to dephosphorylation can be seen 
when run on a 7% Tris-Acetate gel (Fig. 1.4A lower panel).  Upon phosphatase 
treatment, Cdh1 no longer interacted with Bmh1 (compare lane 6 and 9).  However, since 
Cdh1 was purified from WT cells, Acm1 is present.  As shown previously, Acm1 is 
needed for the Cdh1/Bmh1 interaction.  Acm1 contains 5 copies of the consensus CDK 
recognition sequence (S/T-P-x-K/R), and we have observed that Acm1 is heavily 
phosphorylated in normal Cdh1 purifications from asynchronous cells.  From this assay 
we could not conclude whether the dephosphorylation of Cdh1, Acm1, or both that result 
in the diminished binding of Cdh1 with Bmh1.  To determine whether phosphorylation of 
Cdh1 or Acm1 contribute to formation of the complex, we purified N-terminally tagged 
FLAG-Cdh1 from acm1∆ cells and N-terminally tagged HA-Acm1 from cdh1∆ cells, and 
treated each with phosphatase in an in vitro binding assay.  Surprisingly, we found that 
phosphorylation is not needed for the interaction between Cdh1 and Acm1 and the 
addition of Bmh1 had little effect (Fig. 1.4B). To determine whether Acm1 
phosphorylation affects Bmh1 binding, an in vitro binding assay was employed with 
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immobilized GST-Bmh1 incubated with phosphatase treated or untreated FLAG-Acm1 
from cdh1∆ cells. Dephosphorylation of Acm1 abolished binding to Bmh1 indicating that 
phosphorylation of Acm1 but not Cdh1 is critical for the CAB complex formation (Fig. 
1.4C, lanes 4 and 8).   
 
Phosphorylated Cdh1 binds to and activates the APC in vitro and is inhibited by 
complex formation.  Knowing Acm1 has the ability to rescue lethality caused by 
expressing constitutively active Cdh1 with 9 of the 11 CDK sites mutated to alanine, we 
hypothesized partially phosphorylated Cdh1 could still bind and activate the APC.  First, 
we investigated whether in vivo phosphorylated Cdh1 could still bind to the APC in the 
absence of the complex.  To test this notion, we bound Cdh1 to the APC in an in vitro 
binding assay and then used phosphatase treatment on the complex to illustrate all bound 
Cdh1 to the APC is still partially phosphorylated.  N-terminally tagged FLAG-Cdh1 was 
purified from asynchronous acm1∆ cells and incubated with yeast purified APC via 
Apc1-TAP for 30 min. at 4° C.  After incubation with Cdh1, the immobilized APC/bound 
Cdh1 was washed extensively, divided into two columns, and one column treated with λ-
phosphatase.  After treatment, samples were separated by SDS-PAGE and analyzed by 
Western blot.  We found all Cdh1 bound to the APC was phosphorylated.  Samples were 
run on a 6% Tris Glycine gel to differentiate phosphorylated from dephosphorylated 
Cdh1.  A clear mobility shift due to dephosphorylation of bound Cdh1 can be seen from 
untreated and phosphatase treated samples (Fig. 1.5A). We believe the Cdh1 bound to the 
APC is only partially phosphorylated due to the existing evidence that fully 
phosphorylated Cdh1 cannot bind or activate the APC (57,87).  This suggests partial in 
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vivo phosphorylation of Cdh1 in the absence of the complex does not fully inhibit the 
interaction between Cdh1 and the APC.  
Since partial phosphorylation of Cdh1 did not disrupt the interaction with the 
APC, we investigated whether the phosphorylated coactivator could activate the APC.  
From the previous experiments, we knew Cdh1 phosphorylation was not a prerequisite 
for the interaction with Acm1.  So, we also examined whether the addition of Acm1 and 
Bmh1 could attenuate Clb2 ubiquitination using phosphorylated or nonphosphorylated 
Cdh1.  In order to test this, we purified Cdh1 from acm1∆ cells, divided the sample for 
dephosphorylation by phosphatase, and used phosphorylated and dephosphorylated Cdh1 
in the in vitro ubiquitination assay (Fig. 1.5B).  Cdh1 was washed extensively to remove 
phosphatase prior to adding Cdh1 to the assay.  We added equivalent amounts of Cdh1 to 
both sets of reactions.  Both partially phosphorylated and dephosphorylated Cdh1 were 
sufficient for APC mediated ubiquitin ligase activity (lanes 3 and 8).  Upon the addition 
of Acm1 and Bmh1, a decrease in Clb2 ubiquitination can be seen using λ-phosphatase 
treated and untreated Cdh1 (lanes 4, 5, 9, and 10).   Although Cdh1 phosphorylation is 
not necessary for Acm1 binding and inhibition, Acm1 and Bmh1 may exist as an early 
inhibition mechanism of partially phosphorylated Cdh1 before the cyclin dependent 
kinase can fully phosphorylate Cdh1 for inactivation.  Acm1 and Bmh1 may exist as an 
overlapping inhibitory mechanism regardless of the phosphorylation status of Cdh1 to 
ensure proper APC inactivation at the G1/S phase transition and during S phase. 
Discussion 
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Previous work has shown that the phosphorylation of Cdh1 occurs at the end of 
G1 phase by the cyclin dependent kinase Cdc28 and has demonstrated that 
phosphorylation is responsible for the inactivation of the APCCdh1 complex (57,87,99).  
Non-phosphorylatable Cdh1 mutants constitutively activate the APC prohibiting cells 
from accumulating Clb2 and Clb3 (57).  Additionally, in vitro phosphorylation of 
recombinant Cdh1 is convincingly sufficient for inactivation of the APC (87).  There is 
no question phosphorylation of Cdh1 plays an important role in APC inactivation.  
Because the cell cycle follows a very strict schedule, proper and timely inactivation of the 
APC must occur.  Because Cdh1 has been shown to bind substrates independent of the 
APC (33,37,38), one reason for the strict regulation of Cdh1 may be to prevent the co-
activator from interfering with substrates during parts of the cell cycle where it is not 
needed.  It is logical then that cells have overlapping inactivation mechanisms to be sure 
certain cellular processes are disabled.  The possibility remains for novel proteins to exist 
for APCCdh1 inactivation.  Here, we have identified an additional mechanism that acts 
independently of Cdh1 phosphorylation to efficiently inhibit Cdh1 from activating the 
APC.  The mechanism is comprised of complex formation of Acm1 and Bmh1 with Cdh1 
(CAB complex) and functions to inhibit APCCdh1 activity by blocking substrate binding to 
the co-activator.  The CAB complex is the first APCCdh1 inhibitor identified in yeast. 
Acm1 is the critical component involved in complex formation and is cell cycle 
regulated.  Hence, the Cdh1/Bmh1 interaction is confined to the cell cycle interval during 
which Acm1 is expressed.   
We identified Acm1, Bmh1, and Bmh2 as Cdh1 interacting proteins using Cdh1 
immunoprecipitations.  BMH1 and BMH2 appear to be functionally redundant and while 
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deletion of both is lethal in most strains, cells remain viable with the deletion of only one 
of the genes (100,101).  Bmh1 and Bmh2 are members of the 14-3-3 class of proteins 
whose roles include signal transduction, checkpoint control, apoptotic, and nutrient-
sensing pathways, as well as subcellular localization of binding partners (94,102).  14-3-3 
proteins have been defined as phosphoserine-binding proteins with ligands typically 
containing two different binding motifs, RSXpSXP or RXY/FXpSXP, although 
variations of these motifs exist (93,103).  The third member of the complex that forms 
with Cdh1 is a previously uncharacterized protein named Acm1.  Acm1 has been shown 
to interact with Bmh2 via yeast two hybrid assays (104).  Acm1 has been identified as a 
potential Cdc28 substrate and contains five potential CDK phosphorylation sites which 
match the consensus recognition sequence S/T-P-x-K/R (92).  Interestingly, the gene 
expression pattern of Acm1 is similar to that of Clb5, whose accumulation is necessary 
for Cdh1 phosphorylation and S phase entry.  Although we have not seen any significant 
sequence homology of Acm1 in mammalian species, with such an important function, the 
possibility remains an analog exists in higher eukaryotes.   
Inhibition of Cdh1 must occur in a timely manner for S phase to proceed.  Acm1’s 
presence is therefore necessary at the specific time when APCCdh1 needs to be inactivated.  
Indeed, protein levels of Acm1 are highest in S phase coinciding with the 
phosphorylation of Cdh1 by Clb5-Cdc28.  Deletion of Acm1 causes a perturbation in the 
cell cycle leading to an increased population of cells in S phase.  Currently, we cannot 
decipher whether the increased S phase population is a result of early entry into S phase 
or slower progression through S phase.  Additionally, we have observed slightly lower 
Clb2 levels in acm1∆ cells after a G1 arrest and release suggesting an increased APCCdh1 
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activity in the absence of Acm1.  The lower levels of Clb2 occurred in early time points 
under certain growth conditions.  However, Clb2 levels return to a comparable level at 
later time points in the same experiment, which is attributed to effective inhibition of 
APCCdh1 by phosphorylation.  The cell cycle perturbation may not be explained by 
differing Clb2 levels but a longer S phase as a result of lower CDK activity could occur 
(105).  However, our data can only suggest Acm1 has some regulatory role during S 
phase.  Further experiments are needed to determine whether levels of S phase cyclins 
differ in acm1∆ cells.   
Phosphorylation of Cdh1 occurs in S phase and complete phosphorylation 
disrupts the binding interface between Cdh1 and the APC.  We have shown in vivo 
phosphorylated Cdh1 binds to and activates the APC although this result can be 
explained if Cdh1 is only partially phosphorylated. We have demonstrated Acm1 and 
Bmh1 have a direct inhibitory effect on APCCdh1 activity in vitro and in vivo and that 
inhibition by Acm1 and Bmh1 can occur when Cdh1 is phosphorylated or 
dephosphorylated.  Although the phosphorylation status of Cdh1 does not affect CAB 
complex formation, phosphorylation of Acm1 plays a critical role in the assembly of the 
ternary complex with Bmh1 and Cdh1.  We have identified several phosphopeptides 
within Acm1 from Cdh1 immunoprecipitations.  This is not surprising because Acm1 
was originally identified as a potential Cdc28 substrate (92).  Dephosphorylation of 
purified Acm1 has no effect on Cdh1 binding but does abolish Bmh1 binding.  
Phosphorylation of Acm1 and Cdh1 may occur in parallel by the same kinase to mediate 
complex formation.  We have also observed a slight shift in the gel mobility of Acm1 
before it is degraded.  The gel shift could be a result of dephosphorylation perhaps 
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playing a role in Acm1 stability.  Since Bmh1 binds only phosphorylated Acm1 and has 
no inhibitory role by itself, it may serve to protect Acm1 from early degradation.  
Whether or not phosphorylation of Acm1 or if the 14-3-3 proteins are required for 
APCCdh1 inhibition is addressed in the next chapter.  
Potentially, Acm1 and the 14-3-3 proteins are APC substrates.  Protein levels of 
Acm1 drop sharply after S phase when the APC is reactivated.  Although ACM1 mRNA 
expression drops after S phase, the residual Acm1 left over may need to be removed to 
prevent premature inhibition of APCCdh1.  Proteasomal degradation mediated by APCCdc20 
would make sense in order to remove Acm1 until it is needed for APCCdh1 inactivation.  
The destruction box (D box) and the KEN box have been identified as degradation motifs 
in APC substrates (33) while Acm1 contains two potential D boxes (RTIL at aa8 and 
RIAL at aa 119) and a potential KEN box (KENLS at aa 98).  Unlike APC substrates, 
Bmh1 levels are abundant throughout the cell cycle and its levels do not fluctuate.  
Additionally, Bmh1 does not interact with Cdh1 without Acm1 present.  For these 
reasons it is unlikely Bmh1 is an APC substrate.  Further examination of Acm1 as an 
APC substrate is addressed in the next chapter.   
Interestingly, there appear to be some similarities between the APCCdh1 inhibitor, 
Emi1, in higher eukaryotes and the CAB complex in yeast.  Both inhibit APCCdh1 activity 
in vitro and directly bind Cdh1 (62).  Emi1 and Acm1 are both present during S phase 
and are degraded during M phase (69).  In a recent report, a model system has been 
proposed where Emi1 acts as a pseudosubstrate inhibitor of APCCdh1 and competes with 
other D-box containing substrates for Cdh1 binding (63).  Additionally, we have 
observed an interaction between Acm1 and C-terminal fragments of Cdh1 in gel filtration 
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experiments.  The C-terminus of Cdh1 houses a WD-40 domain shown to be the site for 
substrate binding (38).  The mechanism of inhibition including the regions of Acm1 
involved in Cdh1 binding and whether or not Acm1 mimics a substrate to inhibit APCCdh1 
activity will be the focus of the next chapter.  
Cdh1 has been shown to relocalize from the nucleus to the cytoplasm removing it 
from the vicinity of the APC after phosphorylation presumably as a redundant inhibitory 
mechanism (73).  14-3-3 proteins are involved in the relocalization of the cell cycle 
regulatory protein Cdc25, so feasibly Acm1 and Bmh1 could play a similar role with 
Cdh1 (106,107).  However, the possibility of Acm1 and Bmh1 affecting Cdh1 
localization has not been thoroughly investigated.    
Conceivably, additional mechanisms exist for APC inactivation through other 
protein interactions (65,71).  Our evidence suggests that the complex formation serves as 
an overlapping mechanism in addition to the phosphorylation message to efficiently 
inhibit APCCdh1 activity prior to entering mitosis (Fig. 1.6). Additional studies to further 
elucidate the biological significance and mechanism by which CAB complex formation 
inhibits APCCdh1 are illustrated in the next chapter.    
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Table 1 
S. cerevisiae strains used in Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Relevant Genotype Source 
W1588-4c MATa ade2-1 can1-100 His3-11 15 leu2-3 112 trp1-1 
ura3-1 
R. Rothstein 
YKA150 W1588-4c bar1∆::URA3 Hall et al. 
2004 
YKA154 YKA150 CDH1-3FLAG::KanMX4 This Study 
YKA323 YKA150 ypl267w∆::KanMX4 This Study 
DLY3033 MATa bar1::URA3 cdc15-2 ura3 leu2 trp1 J. Pringle 
YKA156 DLY3033 CDC27-3FLAG::KanMX4 This Study 
BY4741 MATa his3-D1 leu2-D0 met15-D0 ura3-D0 Open 
Biosystems 
YPL267W-
TAP 
BY4741 Acm1-TAP::HIS3MX6 Open 
Biosystems 
YKA322 YPL267W-TAP cdh1∆::KanMX4 This Study 
YER177W-
TAP 
BY4741 Bmh1 -TAP::HIS3MX6 Open 
Biosystems 
YNL172W-
TAP 
BY4741 APC1-TAP::HIS3MX6 Open 
Biosystems 
YGL003C∆ BY4741 cdh1∆::KanMX4 Open 
Biosystems 
YPL267W∆ BY4741 acm1∆::KanMX4 Open 
Biosystems 
YER177W∆ BY4741 bmh1∆::KanMX4 Open 
Biosystems 
YDR099W∆ BY4741 bmh2∆::KanMX4 Open 
Biosystems 
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Figure 1.1:  Acm1, Bmh1, and Cdh1 form a ternary complex.  
A, Immunoprecipitations were performed with the yeast strain YKA154 containing Cdh1 
with a 3xFLAG epitope at the C-terminus.  The untagged parent strain was used as a 
control.  Four liters of cells were grown to mid-log phase and arrested in G1 with α-
factor.  Once harvested, cells were lysed and subjected to antibody affinity pulldowns 
using 100 µl of the α-FLAG antibody beads.  Samples were run on 4-12% Bis-Tris gels 
(Invitrogen) and Coomassie stained.  From each lane, gel slices were excised throughout 
the entire length of the gel.  Proteins in each gel slice were digested with trypsin, 
analyzed by mass spectrometry, and identified through subsequent database searching.  
Those proteins present in the sample lane and absent in the control lane were considered 
to interact with Cdh1.  Three proteins known as Bmh1, Bmh2, and a previously 
uncharacterized protein, Acm1, were identified as Cdh1 interacting proteins. B, GST-
Bmh1 from E. coli immobilized on 10 µl GSH beads or Acm1-TAP from 1 L of 
asynchronous yeast cells (OD600=1) immobilized on 60 µl calmodulin affinity beads were 
used in the compact reaction columns for the respective binding assay.  10 µl of purified 
Cdh1-FLAG from 1 L of asynchronous yeast cells or 10 µl of purified GST-Bmh1 were 
incubated with the immobilized protein for 2 hours at 4° C and washed extensively with 
high salt buffer.  Bound proteins were eluted in 1X LDS buffer, run on 4-12% Bis Tris 
gels and transferred to membranes for Western analysis.  I, FT, and E designate input, 
flow through, and elution.  GST immobilized on GSH beads or empty calmodulin beads 
were used as controls.  Immobilized protein shown is Coomassie stained and is 20X 
greater than that shown in binding assay. Cdh1 bound to Bmh1 and Acm1, and Bmh1 
bound to Acm1. C, Cdh1, harboring an N-terminal 3xFLAG epitope transcribed from the 
ADH promoter on a centromeric plasmid, was expressed by transforming the plasmid into 
WT, acm1∆, bmh1∆, and bmh2∆ strains.  Each strain was grown asynchronously in 1 L 
of selective media to OD600=1 before harvesting and pulling down Cdh1 with 25 µl anti-
FLAG M2 antibody-coupled resin (Sigma).  Proteins were separated on a 4-12% Bis-Tris 
gel and Coomassie stained.  *Gel slices from each lane were excised in the region for 
which each protein migrates, digested with trypsin, and analyzed by mass spectrometry in 
order to detect the presence of peptides corresponding to the proteins of interest.  Neither 
Bmh1 nor Bmh2 could be detected in the acm1∆ strain. Bmh1 peptides could not be 
detected in bmh1∆, but Acm1 and Bmh2 were present.  Likewise, Bmh2 could not be 
detected in bmh2∆, but Acm1 and Bmh1 were present. D, Cdh1 was purified from 2 L of 
asynchronous cells grown to OD600=1 from either WT or acm1∆ strains using 50 µl α-
FLAG antibody beads .  GST-Bmh1 was immobilized on 5 µl of GSH beads in compact 
reaction columns.  2 µl of FLAG-Cdh1 purified from WT and acm1∆ cells was incubated 
with the immobilized protein for 2 hours at 4° C and washed extensively with high salt 
buffer.  Bound proteins are eluted in 1X LDS buffer, run on 4-12% Bis Tris gels and 
transferred to membranes for Western analysis.  An α-FLAG antibody was used to detect 
the presence of Cdh1.  The absence of Acm1 abolishes the Bmh1/Cdh1 interaction. 
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Figure 1.2:  Acm1 is expressed in S phase and the deletion of Acm1 leads to an 
enriched S-phase cell population.  A, Strains containing either Acm1 or Bmh1 with a 
C-terminal TAP genomic tag were grown to mid-log phase and arrested in G1 with α-
factor, S phase with hydroxyurea, and M phase with nocodazole.  Cells were harvested, 
lysed and extracts run on 4-12% Bis-Tris gels.  Western analysis using an anti-Protein A 
antibody was performed to measure protein levels in each cell cycle phase.  Acm1 levels 
are highest in S phase while Bmh1 levels remain constant throughout the cell cycle. B, 
Cells from WT and acm1∆ strains were arrested with hydroxurea for synchronization and 
released into fresh media.  Samples were collected in 20 minute intervals for 100 minutes 
after release.  DNA was stained using SYTOX Green (Molecular Probes) and DNA 
content measured on a FACScan instrument for cell cycle progression.  Time points for 
the FACS analysis are present from 20 minutes to 100 minutes.  An enriched S phase 
population was observed at 80 minutes in the acm1∆ strain when compared to WT cells.  
Percentages of G1, S, and G2/M cells for WT and acm1∆ strains at 80 minutes are shown.  
ModFit LT software (Verity Software House, Inc.) was used to calculate percentages of 
G1, S, and G2/M cells. C, Cells from the acm1∆ strain (YKA323) containing the plasmid 
pHLP117 expressing HA-Acm1 from its natural promoter or cells from the same strain 
containing the empty plasmid were grown to mid-log phase and arrested in G1 with α-
factor.  Cells were released from the G1 arrest by washing with 4x the culture volume 
(fresh media) and resuspending washed cells in fresh media.  Time points were taken in 
15 minute intervals.  40 µg of extract was loaded on the gels and probed with an α-HA 
antibody or an α-Clb2 antibody.  The Coomassie stained membranes were used as 
loading controls.  A decrease in Clb2 levels is seen from timepoints 0-45 min.  FACS 
analysis was performed for each 15 minute time point of the G1 arrest and release. 
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Figure 1.3:  Acm1/Bmh1 inhibit APCCdh1 ubiquitin ligase activity by blocking Cdh1 
binding to the APC.  A, Cdh1, Ubc4, and Clb2 used in this assay were produced in the 
TNT T7 Quick coupled in vitro transcription/translation kit and Clb2 was labeled with 
S35 methionine.  APC was purified from yeast and Bmh1 from E. coli. Acm1 was purified 
from 2 L of asynchronous cells grown to OD600=1 using 100 µl of washed calmodulin 
resin.  Resin was washed extensively with APC-C buffer containing 1mM CaCl2 and 
eluted in 2.5 mM EDTA buffer.  15 mM MgCl2 was added to the eluted Acm1 before use 
in the ubiquitination assay.  Components of the assay were mixed and incubated as 
described previously (36).  Ubiquination of Clb2 can be seen as bands of decreasing gel 
mobility.  The triangle represents increasing levels of Acm1.  1x Acm1 is the equivalent 
of 2 µl or 1/50 from the EDTA elution.  Acm1 inhibits APCCdh1 activity in a dose 
dependent manner.  *Control purification from the acm1∆ strain equivalent to 4X 
concentration of Acm1 added.  Levels of unconjugated Clb2 for the quantitation of 
APCCdh1 inhibition by CAB complex formation are shown in the right panel. B, 
Ubiquitination assay is the same as above with the exception of using Cdh1 (p415ADH-
FLAGCdh1 in YPL267W∆) and Acm1 (pHLP107 in YGL003∆) purified from yeast 
using FLAG immunoprecipitations for quantitation.  Ubc4 and Clb2 produced in the in 
vitro transcription/translation kit.  Bmh1 levels used in the assay are sufficient to see by 
Coomassie staining. Levels of APC, Cdh1, and Acm1 used in each assay can be seen in 
the lower panel. C, Cdh1 containing 9 of 11 CDK sites mutated to alanine was 
overexpressed through use of the GAL promoter (pNC219-FLAGCdh1m9 in YKA323).  
In the same strain, pHLP106 expressing FLAG-Acm1 from the GAL promoter was also 
transformed.  Cells were plated on SD-Trp and grown for 48 hours.  Colonies were 
selected and plated on Raf-Trp, grown for 48 hours and replica-plated to Raf-Trp media 
containing galactose.  Extracts (40 µg) were separated by SDS-PAGE and 
immunoblotted with α-FLAG and PGK antibodies.  Cdh1m9 overexpression is lethal 
when expressed without Acm1 (section 5 and lane 5), but lethality is rescued by Acm1 
overexpression (sections 6 and 7, lanes 6 and 7).  Three colonies were tested to ensure 
each contained both transformed plasmids.  Sections 6, 7, and 8 contain both plasmids 
although section 8 exhibited low Cdh1m9 expression.  Extract from control strain without 
plasmids present is shown in lane 9. D, Bacterially expressed GST-Clb2 was incubated 
with FLAG-Cdh1 from acm1∆ cells for 30 min. at 4° C after Cdh1 was pre-incubated 
with varying levels of Acm1.  Clb2 was immobilized on affinity beads.  GST bound to 
GSH beads and GST-Clb2 without Cdh1 were used as controls.  Following incubation 
with Cdh1, columns were washed extensively with high salt APC-C buffer and eluted 
with 1X LDS sample buffer.  Samples were run on a 4-12% Bis-Tris gel and transferred 
for Western blot analysis.  Immobilized protein shown is Coomassie stained and is 20X 
greater than that shown in binding assay.  I, FT, and E designate input, flow through, and 
elution.  Antibodies used for detection are as noted.  Clb2 binding to Cdh1 decreases with 
an increasing concentration of Acm1. E, N-terminally tagged FLAG-Cdh1 was purified 
from either WT or acm1∆ cells and incubated with APC via Apc1-TAP for 30 min. at 4° 
C.  Empty calmodulin beads and APC-TAP without Cdh1 were used as controls.  
Following incubation with Cdh1, columns were washed extensively with high salt APC-
C buffer and eluted with 1X LDS sample buffer.  Samples were run on a 4-12% Bis-Tris 
gel and transferred for Western blot analysis.  Immobilized protein shown is Coomassie 
stained and is 20X greater than that shown in binding assay.  I, FT, and E designate input, 
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flow through, and elution.  Antibodies used for detection are as noted.  The presence of 
Acm1 has no effect on APC/Cdh1 binding. 
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Figure 1.4:  Phosphorylation is involved in the assembly of the CAB complex. 
A, An in vitro binding assay was used with C-terminally tagged Cdh1-FLAG purified 
from WT cells (YKA154) and treated with λ-phosphatase.  Phosphatase treated and 
untreated Cdh1 was incubated with bacterially expressed GST-Bmh1 immobilized on 
GSH affinity beads for 2 hours at 4° C.  Once Cdh1 was bound, columns were washed 
extensively with high salt APC-C buffer and eluted with 1X LDS sample buffer.  I, FT, 
and E designate input, flow through, and elution.  Phosphatase treatment of Cdh1 
abolishes Bmh1 binding. B, An in vitro binding assay was used with N-terminally tagged 
FLAG-Cdh1 and HA-Acm1 treated with λ-phosphatase.  FLAG-Cdh1 was purified from 
2 L of asynchronous yeast cultures grown to OD600=1 and incubated with 100 µl washed 
α-FLAG resin.  Resin was divided and one half treated with phosphatase.  Bound FLAG-
Cdh1 was used as bait.  HA-Acm1 was purified from 2 L of asynchronous cells grown to 
OD600=1 and incubated with 50 µl of washed α-HA resin.  One half was treated with 
phosphatase and eluted 2x in 50 µl low salt APC-C buffer with HA peptide at 100 µg/ml 
final concentration.  1/20 of HA-Acm1 elution was used in each assay and allowed to 
incubate for 1.5 hours at 4 C.  Once bound, the proteins were washed extensively with 
high salt APC-C buffer.  40% of each reaction was loaded on the gel.  A shift in 
dephosphorlation of Acm1 can be seen in the lower panel.  Empty α-FLAG beads were 
used as the control.  Phosphorylation of Acm1 or Cdh1 has no effect on their interaction 
with one another. C, An in vitro binding assay was used with N-terminally tagged and 
bacterially expressed GST-Bmh1.  GST and GST-Bmh1 were prepared as described 
previously.  N-terminally tagged FLAG-Acm1 was purified from 2 L of asynchronous 
yeast cultures grown to OD600=1, purified using 50 µl α-FLAG resin, and one half treated 
with λ-phosphatase.  FLAG-Acm1 was eluted with FLAG peptide (250 µg final conc.) in 
50ul low salt APC-C buffer.  Bound GST-Bmh1 (10 µl GSH beads) was used as bait and 
incubated for 30 min. at 4 C with either phosphatase treated or untreated FLAG-Acm1.  
1/25 of FLAG-Acm1 elution was used in each assay.  Bound proteins were washed 
extensively with high salt APC-C buffer and eluted in LDS sample buffer.  20 % from 
each assay was loaded on the gel.  Nonphosphorylated Acm1 does not interact with 
Bmh1. 
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Figure 1.5:  Phosphorylated Cdh1 is inhibited by complex formation. 
A, N-terminally tagged FLAG-Cdh1 was purified from acm1∆ cells and incubated with 
APC via Apc1-TAP immobilized on calmodulin beads.  After incubation with Cdh1, the 
immobilized APC/bound Cdh1 was washed extensively, divided into two columns, and 
one treated with λ-phosphatase.  After treatment, samples were separated on a 6% Tris-
glycine gel to differentiate phosphorylated Cdh1 from unphosphorylated Cdh1 and 
analyzed by Western blot.  Antibodies used for detection are as noted.  Partially 
phosphorylated Cdh1 can bind the APC. B, Ubc4 and Clb2 used in this assay were 
produced by in vitro transcription/translation.  N-terminally tagged FLAG-Cdh1 was 
purified from 2 L of asynchronous yeast cultures and incubated with 50 µl of α-FLAG 
resin.  The beads were divided, washed extensively with APC-C buffer, and one half 
treated with λ-phosphatase for dephosphorylation.  1/50 of the FLAG-Cdh1 elution was 
used in each assay.  Acm1 was purified from 2 L of asynchronous cells grown to 
OD600=1 using 100 µl of washed calmodulin resin.  Resin was washed extensively with 
APC-C buffer containing 1mM CaCl2 and eluted in 2.5 mM EDTA buffer.  15 mM 
MgCl2 was added to the eluted Acm1 before use in the ubiquitination assay.  The triangle 
represents increasing levels of Acm1.  1x Acm1 is the equivalent of 2 µl or 1/50 from the 
EDTA elution.  Each reaction contains components designated by +/-.  Components of 
the assay were mixed and incubated as described previously.  Ubiquination of Clb2 can 
be seen as bands of decreasing gel mobility.  Partially phosphorylated Cdh1 activates the 
APC, and Acm1 and Bmh1 inhibit phosphorylated Cdh1 preferentially over 
nonphosphorylated Cdh1. 
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Figure 1.6:  Model of APCCdh1 inactivation. 
APCCdh1 is active throughout G1 phase until Cdh1 is phosphorylated by the cyclin 
dependent kinase Cdc28 at the G1/S phase transition.  Additionally, a complex forms 
with the co-activator consisting of Acm1 and Bmh1, which inhibits the APC at the end of 
G1.  The CAB complex dissociates the substrate from Cdh1 and acts independent of Cdh1 
phosphorylation for the timely inactivation of the APC.   
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CHAPTER 3 
 
 
Mechanism for APCCdh1 inhibition by the substrate-like inhibitor Acm1 
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Overview 
 
The anaphase-promoting complex (APC) catalyzes the polyubiquitination of 
numerous proteins that targets them for degradation by the proteasome at specific times 
during the cell cycle.  The Cdh1 and Cdc20 proteins are coactivators that are also 
required for APC activity.  In the previous chapter, we reported the identification of 
Acm1 as an inhibitor of the budding yeast APC both in vitro and in vivo that associates 
with Cdh1 and the 14-3-3 homologs Bmh1 and Bmh2 in a stable, cell cycle-regulated 
complex.  Here we further characterize the Acm1 protein and present a model for how 
Acm1 inhibits APC.  Recombinant Acm1 alone was qualitatively as effective an inhibitor 
of Clb2 ubiquitination in vitro as native Acm1 purified from yeast in the presence of the 
14-3-3 proteins.  Thus, although Acm1 is heavily phosphorylated in vivo, neither 
phosphorylation nor 14-3-3 binding is required for its function as an APC inhibitor.  
Acm1 was specific for the Cdh1-dependent form of APC (APCCdh1) because it potently 
inhibited APCCdh1-catalyzed ubiquitination of Pds1 but had no effect on APCCdc20-
catalyzed Pds1 ubiquitination, even at much higher concentrations.  Acm1 contains 
conserved D-box and KEN sequences that are common to many APCCdh1 substrates and it 
is also rapidly degraded in late M phase like many APC targets.  We found that mutations 
in the D-box and KEN sequences prevent association of Acm1 with Cdh1 in a co-
immunoprecipitation assay, and strongly suppress its ability to inhibit APC both in vitro 
and in vivo.  However, we observed no evidence that Acm1 itself was ubiquitinated 
during reactions in which it completely inhibited Clb2 ubiquitination, and D-box/KEN 
mutants were not stabilized at all in vivo.  We have discovered regions of the N-terminus 
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and C-terminus of Acm1 that prohibit it from being processed as a substrate.  These data 
suggest that the interaction between Acm1 and Cdh1 may be structurally similar to Cdh1-
subtrate interactions but that full length Acm1 is not processed as a substrate. We 
therefore propose that Acm1 is a substrate mimic that inhibits APC by competitive 
exclusion of substrate binding to Cdh1. 
 
   
Introduction 
 
Control of the eukaryotic cell cycle involves a network of tightly regulated 
machinery that governs cell cycle progress.   Progression through the cell cycle is largely 
controlled by cyclin dependent kinases (CDKs) and the timely degradation of proteins. 
The periodic accumulation and destruction of cyclins at key points during the cell cycle 
activate or inactivate CDKs respectively.  Ubiquitin-mediated proteolysis of cyclins is 
one way eukaryotic cells keep proper cyclin levels in check (1-3).  The anaphase- 
promoting complex (APC) is an E3 ubiquitin ligase whose responsibility is to mediate the 
degradation of cyclins and other regulatory proteins during the cell cycle.  The APC 
consists of 13 subunits in yeast with the catalytic core consisting of a cullin homolog 
APC2 and a RING-H2 finger protein APC11 (108).  
Although the APC is present constitutively throughout the cell cycle, APC 
activity is confined to early M phase through G1.  APC activity is triggered by the 
presence of one of two WD40 repeat proteins in mitosis known as Cdc20 and Cdh1 by 
forming distinct complexes, APCCdc20 or APCCdh1.  Cdc20 and Cdh1 control substrate 
specificity by associating with particular substrates at certain times throughout the cell 
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cycle (25,29,35).  Cdc20 activates the APC during M phase and triggers the metaphase to 
anaphase transition after marking Pds1 for degradation (13).  Cdh1 activates the APC 
once it is dephosphorylated by Cdc14 phosphatase at the end of M phase (87).  APCCdh1 
activity leads to the onset and maintenance of G1 and prevents premature S phase entry 
(34).   
Regulation of APCCdc20 involves targeting Cdc20 for degradation by APCCdh1 
(60).  Means of APCCdh1 regulation include the phosphorylation of Cdh1 by Clb5-CDK at 
the end of G1 rendering APCCdh1 inactive (57).  Other means of Cdh1 regulation involve 
its re-localization to the cytoplasm presumably to remove Cdh1 from the vicinity of the 
APC (109).  In vertebrates, Emi1 has been shown to bind and inhibit Cdh1 by mimicking 
an APC substrate (63).  Other protein-protein interactions have been described in the 
regulation of both APCCdc20 and APCCdh1 although until recently, no known inhibitors for 
APCCdh1 had been discovered in yeast (69,71,110).   
In the previous chapter, we reported a new protein-protein interaction in yeast 
between Cdh1 and Acm1 (111,112).  The function of Acm1 was characterized as an 
APCCdh1 inhibitor independent of Cdh1 phosphorylation.  Acm1 forms a complex with 
Cdh1 and members of the 14-3-3 family of proteins, Bmh1 and Bmh2, in late G1 
throughout S phase.  Acm1 levels oscillate during the cell cycle and are highest in S 
phase.  The presence of phosphorylated Acm1 is required for the complex to form, thus 
complex assembly is restricted to the cell cycle window in which Acm1 is expressed.  
Upon the addition of Acm1 and Bmh1, APCCdh1 activity decreases in vitro in a dose 
dependent manner.  Additionally, we showed overexpression of Acm1 could rescue the 
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lethality caused by overexpressing WT Cdh1 or the constitutively active Cdh1 
phosphomutant.   
Acm1 functions as an inhibitor by blocking Clb2 binding to Cdh1 but not binding 
to the APC.  Although Acm1 has been shown to be an effective APCCdh1 inhibitor, the 
mechanism and specificity of inhibition are not clear.  Here, we report additional 
properties of APCCdh1 inhibition by Acm1, providing a clearer picture of the primary 
mechanism of action of Acm1.  We demonstrate that neither the presence of the 14-3-3 
proteins nor Acm1 phosphorylation is necessary for inhibition of APCCdh1 activity by 
Acm1.  Acm1 contains APC substrate-like regions known as D boxes and a KEN box 
that when mutated abolish the interaction with Cdh1.  The C-terminus of Cdh1, 
containing the WD40 repeat domains implicated in substrate binding, is also the region of 
Acm1 binding (38).  Although Acm1 binds the C-terminal region of Cdh1 like other APC 
substrates, it is not ubiquitinated by the APC until the N-terminus and C-terminus are 
truncated.  Together, we suggest Acm1 functions as an APCCdh1 inhibitor by mimicking 
an APC substrate.  
  
Experimental Procedures 
 
Plasmid construction.  Mutations in the D-box and KEN sequences of ACM1 were 
created in pHLP117 (112) using the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene).  All D-box mutations resulted in RxxL to AxxA substitutions, and the KEN 
box was changed to AAA.  The five CDK consensus phosphorylation sequences in Acm1 
were changed to alanine in similar fashion and subcloned with a single HA epitope into 
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the XbaI and XhoI sites of p415GAL1 to create pHLP110 expressing an N-terminal HA 
epitope fusion from the galactose-inducible GAL1 promoter.  ACM1 with a 3XFLAG 
epitope was cloned into the NcoI and NotI sites in the pIVEX-2.3d vector (Roche) for 
bacterial expression. 
 
APC Purification.  2 L of cells from YKA156 were grown to OD600=0.5 at 25° C and 
temperature shifted to 37° C for 2 hours.  Cells were lysed in 1 volume of APC-C lysis 
buffer (25mM HEPES-NaOH pH 7.5, 400mM NaCl, 10% glycerol, 0.1% Triton X-100, 
0.1mM dithothreitol, 0.5mM PMSF, and complete protease inhibitor cocktail (Roche)) by 
vortexing for 45 min. at 4° C in 1.7 ml microcentrifuge tubes containing 0.5 ml 0.5 mm 
glass beads. Cell lysate was cleared by centrifugation at 16,000 x g for 15 min.  Soluble 
extracts were pooled and cleared a second time at 5000 rpm for 5 min.  Extracts from 
YKA156 were incubated with EZView anti-FLAG M2 antibody-coupled resin (Sigma) 
for 1.5 hrs. at 4° C, washed extensively with APC-C buffer and eluted 2X with FLAG 
peptide (250 µg/ml) in low salt APC-C buffer (25mM HEPES-NaOH pH 7.5, 150mM 
NaCl, 10% glycerol, 0.1% Triton X-100, 0.1mM dithothreitol).   
 
Acm1 purification.  Overnight cultures of E. coli harboring ACM1 in the pIVEX-2.3d 
vector were grown and used to inoculate 1L of 2XYT (16g/L tryptone, 10 g/L yeast 
extract, 5 g/L NaCl) containing 100 µg/ml ampicillin.  Bacterially expressed 3XFLAG-
Acm1 was grown at 37° C to OD600=0.8 and IPTG added to induce protein expression.  
Cells were grown for three additional hours and harvested.  Cell pellet was washed with 
water and resuspended in 4 volumes of cold lysis buffer (50mM NaPO4 pH 7.5, 500mM 
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NaCl, 10% glycerol) on ice.  Lysozyme was added to 1 mg/ml and incubated on ice for 
30 min.  Triton X-100 was added to 1% along with PMSF to 1mM and pepstatin to 1 µM.  
Mixture was sonicated with brief pulses until the viscosity was reduced to water-like 
consistency.  Lysate was spun at 35,000 x g for 30 min.  Supernatant was incubated with 
500 µl of anti-FLAG resin and incubated for 1 hour at 4° C.  Resin was washed 4X with 
25 ml lysis buffer.  Acm1 was eluted 2X with 250 µg/ml of 3XFLAG peptide.  Acm1 
purified from yeast using pHLP117 and pHLP149 (3D box/KEN mutant) transformed 
into acm1∆ cells (YKA150 background) were grown asynchronously to OD600=1 and 
lysed in 1 volume APC-C lysis buffer in the same manner as for APC.  Cell extracts were 
incubated with 100 µl of EZView anti-HA antibody-coupled resin (Sigma) for 1.5 hrs at 
4° C.  Resin was 2X with APC-C buffer and then 2X with low salt APC-C buffer.  Bound 
protein was eluted with 100 µg/ml HA peptide in low salt APC-C buffer.  Acm1 
(pRSET-FLAG-Acm1) used in the ubiquitination assay was made using the TNT T7 
Quick coupled in vitro transcription/translation kit (Promega). 
 
Co-IP and Western blotting.  Coimmunopurification (Co-IP) experiments testing 
interactions between 3FLAG-Cdh1 and D-box/KEN mutant HA-Acm1 were performed 
as described by M. Hall (112). Briefly, soluble yeast extracts were incubated with anti-
FLAG M2 resin (Sigma) to bind 3FLAG-Cdh1. Resin was washed with Buffer C (50mM 
sodium phosphate [pH 7.5], 100mM NaCl, 10% glycerol, 0.1% Triton X-100, 50mM β-
glycerophosphate) supplemented with 0.5mM dithiothreitol, 0.5mM 
phenylmethylsulfonyl fluoride, 1µM pepstatin, 100µM leupeptin, and 5mM EDTA, and 
3FLAG-Cdh1 eluted with 250 µg/ml 3FLAG peptide (Sigma). FLAG and HA signals in 
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the eluate were measured by immunblotting. 
 
Cell-cycle expression profiles of D-box/KEN mutant Acm1.  W1588-4c containing 
plasmids with wild-type or D-box/KEN mutant 3HA-Acm1 expressed from the natural 
ACM1 promoter were synchronized with α-factor or nocodazole, released from arrest and 
the expression level of Acm1 monitored at incremental timepoints by immunoblotting as 
described by M. Hall (112).  
 
Ubiquitination assay.  Ubiquitination assays were carried out as described by D. Barford 
(36).  The substrates Clb2 (pRSETClb2) and Pds1 (pRSETPds1), the co-activators Cdh1 
(pET28-His6-Cdh1) and Cdc20 (pET28-His6-Cdc20), and the E2 Ubc4 (pET28-His6-
Ubc4) were prepared using the TNT T7 Quick coupled in vitro transcription/translation 
kit (Promega).  APC (YKA156) and Acm1 were purified from budding yeast (see APC 
and Acm1 purification).  APC used in each reaction was 1/50 of the elution from 2 L of 
cells.  Clb2, Pds1, and Acm1 were radiolabeled with S35 methionine (Perkin Elmer).   
Reactions were run on a 4-12% Bis-Tris NuPAGE gel (Invitrogen), dried, and imaged 
using Hyperfilm (Amersham Biosciences). 
 
In vivo APC/C inhibition assay.  Inhibition of APC/CCdh1 activity in vivo was 
determined by monitoring the effect of overexpression of ACM1 alleles on the toxicity of 
Cdh1 overexpression as described by M. Hall (112).  
 
Results 
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Acm1 does not require the 14-3-3 proteins or phosphorylation to act as a specific 
APCCdh1 inhibitor.  Previously, we identified Acm1 in a Cdh1 pulldown in a complex 
with Bmh1 and Bmh2.  The interactions of Bmh1 and Bmh2 were dependent on the 
presence of phosphorylated Acm1 while the formation of the Cdh1/Acm1/Bmh1 complex 
was shown to inhibit APCCdh1 activity.  Additionally, we observed no inhibition of APC 
activity with the addition of Bmh1 alone.  Since Acm1 mediates the interaction between 
the 14-3-3 proteins and Cdh1, the interaction between Acm1 and Cdh1 was examined in 
greater detail.  To decipher whether Acm1 could act as an inhibitor without the 14-3-3 
proteins or phosphorylation, Acm1 was purified from E. coli and tested for its ability to 
inhibit APCCdh1 activity in an in vitro ubiquitination assay.  Non-phosphorylated Acm1 
from E. coli in the absence of 14-3-3 proteins inhibited APCCdh1 activity in vitro in a 
dose-dependent manner using Clb2 as a substrate (Figure 2.1A).  Levels of Acm1 used 
were comparable to those used in the previous chapter for inhibition of APCCdh1 (Figure 
1.3B).  In addition, we made an Acm1 mutant with all 5 consensus CDK sites mutated to 
alanine to see if overexpression of this mutant could rescue the lethality caused by Cdh1 
overexpression in vivo.  As seen in Figure 2.1B, overexpression of Cdh1 alone is lethal 
while both WT and the Acm1 CDK mutant can rescue this lethality.  The Acm1 CDK 
mutant does not interact with Bmh1 and Bmh2 in co-immunoprecipitation experiments 
further emphasizing that the 14-3-3 proteins are not needed for APC inhibition (data not 
shown).  Together, our results demonstrate that the primary mechanism for APCCdh1 
inhibition is through Acm1 binding to Cdh1 and that neither Bmh1 or Bmh2 nor Acm1 
phosphorylation is required for this inhibition. 
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The Acm1 KEN box and D box regions mediate the interaction with Cdh1.  Both 
KEN boxes and D boxes have been shown to be involved in substrate interactions with 
Cdh1 and Cdc20 (33,37).  Interestingly, Acm1 contains three D boxes and one KEN box 
in Saccharomyces cerevisiae with the first and third D box regions and the KEN box 
being highly conserved in other budding yeast species (Figure 2.2A).  Since Acm1 binds 
directly to Cdh1, we questioned which regions of Acm1 were involved in the interaction 
with Cdh1.  To test this, we mutated each of the three consensus D box regions and the 
KEN box region to systematically decipher if any of these regions singly or in 
combination affected the Acm1/Cdh1 interaction.  Immunoprecipitations of Cdh1 were 
performed from cells co-expressing each of the different Acm1 mutants.  Mutations in the 
third D box and the KEN box decreased the binding affinity of Acm1 to Cdh1 (Figure 
2.2B, lanes 3 and 4).  With both the third D box and KEN box mutated together, binding 
between Acm1 and Cdh1 was completely abolished (Figure 2.2B lane 7).  In vivo, the 
double mutant (3D box and KEN box) was only able to partially rescue lethality caused 
by Cdh1 overexpression (Figure 2.2C).  The double mutant was also used in the in vitro 
ubiquitination assay to test whether the mutant could still act as an APCCdh1 inhibitor.  In 
comparison to WT Acm1, there was no decrease in Clb2 ubiquitination by the mutant 
Acm1 (Figure 2.2D).  Therefore, the third D box and KEN box of Acm1 are required for 
its interaction with Cdh1 and its ability to act as an inhibitor. 
    
Acm1 binds the WD40 repeat containing region of Cdh1.  The WD40 propeller 
domain of Cdh1 has been shown to be the D box receptor for APC substrates (38).  Since 
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Acm1 contains substrate-like D boxes and a KEN box, we hypothesized Acm1 should 
bind to the WD40 domain of Cdh1.  In order to test this, we generated an N-terminal 
fragment (aa 1-249) of Cdh1 containing the prominent CDK phosphorylation sites and a 
C-terminal fragment (aa 241-end) containing the WD40 domains.  Immumoprecipitations 
of with each Cdh1 truncation resulted in Acm1 binding to only the Cdh1 C-terminal 
fragment (Figure 2.3A).  Additionally, the C-terminal fragment of Cdh1 is capable of 
pulling down Bmh1 and Bmh2 in addition to Acm1 (Figure 2.3B). 
In Chapter 2, we discussed the decrease in binding we observed between Cdh1 
and Clb2 upon the addition of increasing Acm1 concentrations.  This result suggested 
Acm1 out-competed Clb2 for Cdh1 binding.  Together, with the substrate like regions of 
Acm1 and the Cdh1 substrate binding region involved in this interaction, our results 
suggest Acm1 acts as a competitive, substrate-like inhibitor.   
 
Acm1 is a specific inhibitor of the Cdh1-dependent APC and is not ubiquitinated by 
the APC.  Acm1 was first identified as a Cdh1 interacting protein and APCCdh1 inhibitor.  
Because Acm1 could inhibit APCCdh1 activity, our next question was whether Acm1 
could also inhibit APCCdc20 as a multifunctional APC inhibitor.  To test this notion, Acm1 
levels 5X greater than those used to efficiently inhibit APCCdh1 activity were added to an 
in vitro APCCdc20 ubiquitination assay.  Acm1 did not inhibit Pds1 ubiquitination by 
APCCdc20 but clearly inhibited APCCdh1 mediated Pds1 ubiquitination (Figure 2.4A, lanes 
3 and 6).  
Since Acm1 appears to act as a specific Cdh1 inhibitor by competing for substrate 
binding to the co-activator, we questioned whether Acm1 could be ubiquitinated or 
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degraded in an APC specific manner while acting as an inhibitor.  In order to test this 
hypothesis, we employed an in vitro ubiquitination assay using the APCCdh1 complex.  
APCCdh1 does not appear to be able to ubiquitinate full length Acm1 in vitro although 
Acm1 levels are sufficient for inhibition (Figure 2.4B, lanes 3 and 5).  Truncations of 
Acm1 were made to test whether certain regions prohibited Acm1 from being processed 
as an APC substrate.  When both the N-terminus and C-terminus of Acm1 are truncated, 
Acm1 is ubiquitinated by APCCdh1 suggesting these regions are responsible for the ability 
of Acm1 to serve as an APC inhibitor (Figure 2.4C, 42-140).  Additionally, the 3D 
box/KEN box mutant of Acm1, previously shown to completely disrupt binding to Cdh1, 
was transformed into acm1∆ cells and a block/release time course performed to measure 
the stability of the Acm1 mutants compared to WT Acm1.  No difference was observed 
in Acm1 stability between the Acm1 mutants and WT Acm1 in a G1 phase arrest and 
release experiment further suggesting APC does not play a role in Acm1 degradation 
(Figure 2.4D).  These results also suggest that Acm1 mimicks an APC substrate in order 
to serve as a potent APCCdh1 inhibitor.  
 
Discussion 
 
Upon identifying Acm1 in Cdh1 immunoprecipitations, our immediate 
assumption was that Acm1 was a novel APCCdh1 substrate.  Further investigation revealed 
Acm1 functioned to inhibit APCCdh1 activity by blocking substrate binding to Cdh1.  
Acm1 does contain APC substrate-like D boxes and a KEN box, and by mutating these 
substrate-like regions, the interaction between Acm1 and Cdh1 was abolished.  In 
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addition, we found Acm1 binds to the substrate binding WD40 repeat region of Cdh1.  
Therefore, Acm1 looks like an APC substrate but is an APC inhibitor.  The question is 
then raised, could Acm1 be both a novel APC substrate and APC inhibitor 
simultaneously?  Acm1 levels are highest during S phase and lowest during M phase and 
G1.  If Acm1 was degraded during M phase by ubiquitin-mediated proteolysis, APCCdc20 
could be the likely E3 ligase responsible.  In order to investigate the possibility of Acm1 
acting as both an inhibitor and substrate, we employed an in vitro ubiquitination assay 
using the radiolabled substrates Pds1 and Clb2 and radiolabled Acm1.  As a result Acm1 
does not act as an inhibitor of APCCdc20 suggesting Acm1 does not block substrate 
binding to Cdc20 as it does with Cdh1.  Although Acm1 acts as an inhibitor of APCCdh1, 
it does not appear to be ubiquitinated as an APCCdh1 substrate in vitro until both the N-
terminus and C-terminus are removed.  When these regions were truncated, Acm1 is 
converted to an APCCdh1 substrate.  Additionally, the pattern of Acm1 oscillation during 
cell cycle progression did not change when using the Acm1 3D box/KEN box double 
mutant.  Because D box and KEN box regions are present in both APCCdc20 and APCCdh1 
substrates, this data further suggests Acm1 is not likely an APC substrate.  Acm1 appears 
to function solely as an APCCdh1 inhibitor and may be targeted for degradation by other 
means.   
We have shown the ability of Acm1 to inhibit APCCdh1 activity is not enhanced by 
the presence of the 14-3-3 proteins, Bmh1 and Bmh2 or by Acm1 phosphorylation.  An 
interesting question is to why the 14-3-3 proteins are present in a complex with Cdh1 and 
Acm1.  Although the roles for 14-3-3 proteins range from signal transduction to the 
relocalization of proteins, they have been commonly shown to bind phosphoproteins 
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(93,113).  We have shown phosphorylation of Acm1 is required for the 14-3-3 proteins to 
bind.  Because we have also observed instability of Acm1 with all CDK sites mutated to 
alanine in cells (data not shown) and a down shift in gel mobility prior to its 
disappearance in the cell cycle (Chapter 2, Figure 1.2C), we believe one possible role for 
the 14-3-3 proteins may be to protect Acm1 from premature degradation.  However, 
further examination is required to elucidate the role of Bmh1 and Bmh2.     
Acm1 appears to act as an APCCdh1 inhibitor by mimicking an APC substrate.  
Evolutionarily, this mechanism makes complete sense to out-compete substrate binding 
in order to shutoff enzymatic activity.  However, proteins mimicking substrates as a 
means of inhibition is not a novel concept and has been illustrated in several different 
systems.  The phosphoprotein, hnRNP-U, has been shown to occupy the receptor subunit 
of the SCFβ-TrCP as a pseudosubstrate perhaps as a way to block substrate binding to the 
SCF (114).  Additionally, the BPS region of Grb14, a tissue-specific negative regulator of 
insulin receptor signaling, binds as a psuedosubstrate inhibitor (115).  In vertebrates, 
Emi1 has been characterized as mimicking an APC substrate to inhibit APCCdh1 (63).  
Although Acm1 and Emi1 act as APCCdh1 inhibitors by mimicking APC substrates, there 
are key differences between the two proteins.  When Emi1 is phosphorylated, it is 
converted to a SCF substrate.  Although we have not yet determined how Acm1 levels 
are regulated during the cell cycle, we do know Acm1 phosphorylation aids in its 
stability.  In addition, Acm1 and Emi1 share no sequence homology.  Evolutionarily, it is 
possible as these species diverged, the same need was present to inhibit APCCdh1 by 
additional means other than phosphorylation.  Potentially, what once was an APC 
substrate was converted to an inhibitor through mutation of one or more regions of the 
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substrate.  However, further experiments are needed to determine the ultimate fate of 
Acm1. 
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Table 2 
S. cerevisiae strains used in Chapter 3 
 
 
 
 
Strain Relevant Genotype Source 
W1588-4c MATa ade2-1 can1-100 His3-11 15 leu2-3 112 trp1-1 
ura3-1 
R. Rothstein 
YKA150 W1588-4c bar1∆::URA3 Hall et al. 
2004 
YKA254 W1588-4c acm1∆::KanMX4 This Study 
YKA323 YKA150 acm1∆::KanMX4 This Study 
BY4741 MATa his3-D1 leu2-D0 met15-D0 ura3-D0 Open 
Biosystems 
YKA245 BY4741 cdh1∆::KanMX4 3HA-Acm1 bar1∆::URA3 This Study 
YKA237 BY4741  acm1∆::KanMX4 This Study 
YKA294 BY4741 bar1∆::HisG 3FLAG-Cdh1 
acm1∆::KanMX4 
This Study 
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FIGURE 2.1 
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Figure 2.1:  Acm1 does not require 14-3-3 proteins or phosphorylation to act as an 
APC inhibitor. 
A, Cdh1, Ubc4, and Clb2 used in this assay were produced in the TNT Quick coupled in 
vitro transcription/translation kit.  Clb2 was labeled with S35 methionine.  APC was 
purified from yeast extracts while Acm1 was purified from E. coli.   Ubiquitinated Clb2 
can be seen as bands of decreasing gel mobility.  Nonphosphorylated Acm1 inhibits 
APCCdh1 activity in a dose-dependent manner.  B, Liquid YKA150 cultures containing 
empty control plasmids or single-copy GAL1 expression plasmids (pHLP163 for 3FLAG-
CDH1, pHLP109 for HA-ACM1, pHLP110 for HA-ACM1-5A, and pHLP111 for HA-
ACM1-5E) were grown in selective raffinose medium, and 10-fold serial dilutions were 
spotted and grown on selective medium containing either glucose or galactose.  Acm1 5A 
has all five consensus CDK sites on Acm1 mutated to alanine.  Acm1 5E has all five 
consensus CDK sites mutated to glutamic acid.  Both Acm1 CDK mutants inhibit 
APCCdh1 activity in vivo. 
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S. cerevisiae Acm1p        ----MISPSKKRTILSSKNINQK------PRAVVKGNELRSPSK-RRSQI 39 
A. gossypii ACR025Wp       --MSDVSPVK-RNVLARKSVNVKAG----ARKDKNNSNQSSPKR-AKIES 42 
K. lactis XP_453099.1      -MIQHRSPLKKRAVLTSKNVNIISTGNSITKPTGSTSSHGSPRR-IKTKL 48 
D. hansenii CAG85940.1     ----MSSPMH-RPILSPKHSNSRSASPIKNDKTFMAQQIESPYNNQRIRL 45 
C. albicans CaO19_12964    MSSNQTSPVR-RSILSPKPSN------LTNNNSPLGKRFNTSS-----RL 38 
                                 ** : * :*: *  *               .   :.      .   
 
S. cerevisiae Acm1p        DTDYALRR---SPIKTIQISK-----------AAQFMLYEETAEERNIAV 75 
A. gossypii ACR025Wp       SESSVTTGRVASPLRPSG----------------QFTFYKETPEERAQVI 76 
K. lactis XP_453099.1      DVERALQK---SPVKQVFSIKRGSPKKKGDDDPSSFAFYEESEEDRAVAL 95 
D. hansenii CAG85940.1     SYNNINNT---SPSKKPQVKKLVSPTKARPSKELSFTIFEDDVYYRDTLT 92 
C. albicans CaO19_12964    TP---------SPSKSGYHRSSATPSPKK--QTLGFTIWEDKVDKSNSTT 77 
                                      ** :                    * ::::              
 
S. cerevisiae Acm1p        HRHNEIYNN--------NNSVSNENNPSQVKEN-LSPAKICPYERAFLRE 116 
A. gossypii ACR025Wp       QQQTTVAQQ--------RVR--DENDFESCKEN--LDCEETAKTGAAAGK 114 
K. lactis XP_453099.1      MRHVSLRRK--------AVHDENEQELENIDENKLAKVRAQATQNRGSNG 137 
D. hansenii CAG85940.1     DDTKPDEEPLGKENDSIETVRESRNKLNHDDQENILQPKFKQSTLKQASI 142 
C. albicans CaO19_12964    DVVG----------------TPTSNKLNHNDQENILQPKKVENKRFHN-- 109 
                                                   :. .  .::     .                
 
S. cerevisiae Acm1p        GGRIALKDLSVDEFKGYIQDPLTDETIPLTLPLGD-----------KKIS 155 
A. gossypii ACR025Wp       PSRTALRDLSIEEYCGYIEYKGGSSRNQLTLHLA------------HPTV 152 
K. lactis XP_453099.1      TAISPLQDLDIELFPGTIQYRGFSQEHHLNLHLN------------HTRK 175 
D. hansenii CAG85940.1     ARRKPLSNLNINEFSGYVTYN-QFPIQLNELYQPPNFQNELKSIHKFNSK 191 
C. albicans CaO19_12964    -DRQPLSNLSINEFKGFISTNGGAPIQLTELYQPINFDNEFKSLHKQ-SN 157 
                               .* :*.:: : * :            *                    
 
 
S. cerevisiae Acm1p        LPSFITPPRN-------------------------SKISIFFTSKHQGQ- 179 
A. gossypii ACR025Wp       LPSFVTPPRS-------------------------AKLRAFFTAKQVVK- 176 
K. lactis XP_453099.1      LPEYITPPRN-------------------------AKLKDFFVHETHVN- 199 
D. hansenii CAG85940.1     LPCFVTPPRSNLQNGLLTSKYLVKSAIEEEPFNEEDEVEHRLMQKHSS-- 239 
C. albicans CaO19_12964    IPSYVTPSRR------YRDKYLVKSGIDEIDEEIEDEMELLLSKKQQQRS 201 
                           :* ::**.*                           ::   :  :          
 
S. cerevisiae Acm1p        ---------------NPE-TKISRSTDDVSEKKVVRKLSFHVYEDE 209 
A. gossypii ACR025Wp       ---------------SKRRCKRAKTTDDICKDRTVRKLDFTIHQDA 207 
K. lactis XP_453099.1      ---------------DKD-QVFSKTTDDINANKVVRKLQFCIDENR 229 
D. hansenii CAG85940.1     ---------------IKKR-RSLSVGKNDSKFKLIKKNNFQILTN- 268 
C. albicans CaO19_12964    TTLSAKPNNINKTHLIRKHTRSLSVGKNNSKLNLIRKNKFSILSN- 246 
                                                     .:    . ::* .* :  : 
 
1 2 3 4 5 6 7 8
A 
B 
D 
C
FIGURE 2.2 
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Figure 2.2:  The Acm1 KEN box and 3-D box regions mediate the interaction with 
Cdh1. 
A, ClustalW sequence alignment of D-box and KEN box regions (highlighted in yellow) 
and consensus CDK sites (S/T-P-X-K/R) highlighted in grey with other yeast species.  B, 
Co-immunoprecipitation with Cdh1 and Acm1 D/KEN box mutants.  1D mutant contains 
the mutation in the 1st D box of Acm1.  3D contains mutations in the 3rd D box of Acm1.  
K mut contains a mutation in the KEN box of Acm1.  3mut contains mutations in the 1st 
and 3rd D box regions as well as in the KEN box of Acm1.  The 3D and KEN box 
mutations together abolish interaction with Cdh1.  C, In vitro ubiquitination assay using 
3D/KEN box Acm1 mutant verses WT Acm1. Cdh1, Ubc4, and Clb2 used in this assay 
were produced in the TNT Quick coupled in vitro transcription/translation kit.  Clb2 was 
labeled with S35 methionine.  APC and Acm1 were purified from yeast extracts as 
described. Ubiquitinated Clb2 can be seen as bands of decreasing gel mobility.  WT 
Acm1 inhibits APCCdh1 activity but the Acm1 mutant does not.  D, Liquid YKA150 
cultures containing empty control plasmids or single-copy GAL1 expression plasmids 
pHLP163 for 3FLAG-CDH1, pHLP109 for HA-ACM1, and pHLP126 for HA-ACM1-
3mut) were grown in selective raffinose medium, and 10-fold serial dilutions were 
spotted and grown on selective medium containing either glucose or galactose.  WT 
Acm1 rescues lethality caused by Cdh1 overexpression, but the 3mut version of Acm1 is 
unable to fully rescue the lethality.  
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Figure 2.3:  Acm1 binds the WD-40 domain region of Cdh1. 
A, Plasmids containing either the N-terminal or C-terminal fragment of Cdh1 were 
transformed into YKA245 expressing 3HA-ACM1 and co-immunoprecipitated with 
Cdh1.  The N-terminal region of Cdh1 (1-249) contains the prominent CDK 
phosphorylation sites while the C-terminus (241-end) houses the WD-40 domains.  Acm1 
interacts with only the C-terminal domain of Cdh1.  B,  The C-terminus of Cdh1 is 
capable of pulling down the entire Acm1/Bmh1/Bmh2 complex.   
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Figure 2.4:  Acm1 is a specific APCCdh1 inhibitor and is not degraded in an APC 
dependent manner. 
A, In vitro ubiquitination assay using recombinant Acm1 for inhibition.  Cdh1, Cdc20, 
Ubc4, and Pds1 used in this assay were produced in the TNT Quick coupled in vitro 
transcription/translation kit.  Pds1 was labeled with S35 methionine.  APC was purified 
from yeast extracts as described.  Ubiquitinated Pds1 can be seen as bands of decreasing 
gel mobility.  Levels of Acm1 5X greater than required for complete APCCdh1 inhibition 
were not sufficient for inhibition of APCCdc20.  B, In vitro ubiquitination assay using 
Cdh1, Ubc4, Clb2, and Acm1 produced in the TNT Quick coupled in vitro 
transcription/translation kit.  Clb2 and Acm1 were both labeled with S35 methionine.  
APC was purified from yeast extracts as described.  Ubiquitinated Clb2 can be seen as 
bands of decreasing gel mobility.  Full length Acm1 made in the IVTX system can inhibit 
APCCdh1 activity but is not ubiquitinated by Cdh1-dependent APC.  C, In vitro 
ubiquitination assay using Cdh1, Ubc4, Clb2, and Acm1 produced in the TNT Quick 
coupled in vitro transcription/translation kit.  Truncations of Acm1 were made and 
designated based on the numbers of amino acids in the sequence.  Full length (FL) Acm1 
includes amino acids 1-209.  The N-terminal truncation of Acm1 is designated 42-209.  
The C-terminal truncation of Acm1 is designated 1-140 and Acm1 with both termini 
truncated is designated 42-140.  Clb2 and Acm1 were both labeled with S35 methionine.  
APC was purified from yeast extracts as described.  Ubiquitinated Clb2 and Acm1 can be 
seen as bands of decreasing gel mobility.  Acm1 with both termini truncated (42-140) can 
be ubiquitinated by APCCdh1.  D, G1 phase block and release experiment following levels 
of wild-type Acm1 and the Acm1 mutant (1st and 3rd D box and KEN box mutated) 
throughout the cell cycle.  Cells were synchronized with nocodazole, released, and Acm1 
levels measured after the release.  No change between Acm1 levels between WT and the 
Acm1 mutant are observed suggesting Acm1 levels are not controlled by APC activity. 
    
CHAPTER 4 
 
 
 
General Discussion 
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Regulation of the anaphase-promoting complex has been shown to be crucial to 
maintaining strict cell cycle control ensuring proper progression.  Misregulation of the 
APC co-activators, Cdc20 and Cdh1, has been linked to various cancers.  For example, 
upregulation of Cdc20 has been shown in lung and gastric cancers while downregulation 
of Cdh1 has been observed in the malignant progression of a B-lymphoma cell lines 
(75,79).  Hence, the study of APC regulation through the co-activators is important for 
better understanding the cellular processes involved to ultimately design therapeutics to 
treat cancer.   
At the inception of this work, regulation of the APC co-activator Cdh1 in budding 
yeast was known to occur in several ways.  The first and most characterized means of 
shutting off APCCdh1 activity is through Cdh1 phosphorylation by the cyclin dependent 
kinase Cdc28.  Phosphorylation is thought to disassociate Cdh1 from the APC thereby 
inactivating APC activity.  Other means of regulation include the cell cycle mediated 
relocalization of Cdh1 during S phase from the nucleus to the cytoplasm.  This 
mechanism is in place presumably to remove Cdh1 from the vicinity of the APC, which 
is always nuclear.  Additional mechanisms for Cdh1 negative regulation exist in other 
species but before this work, no protein inhibitors of APCCdh1 activity had been identified 
in budding yeast.  The work reported in the previous chapters encompasses the journey 
from identification to characterization of function to the detailed mechanism of APCCdh1 
inhibition by Acm1.     
The identification of interacting proteins with the APC co-activator Cdh1 began 
as a proteomic study of novel APC associated proteins using highly sensitive mass 
spectrometric techniques.  At our disposal was an arsenal of mass spectrometers capable 
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of analyzing very low-level proteins, ideal for identifying potentially undiscovered 
interacting proteins of one of the most studied regulatory machines in the cell cycle.  As a 
result, three novel interacting proteins of Cdh1 were identified.  Two of the identified 
proteins were members of the 14-3-3 family of proteins known as Bmh1 and Bmh2.  14-
3-3 proteins have been linked to a multitude of cellular processes including relocalization 
of proteins from the nucleus to the cytoplasm.  The third protein identified that interacted 
with Cdh1, Acm1, was an uncharacterized protein whose identity was linked to Cdc28 as 
a potential substrate.  Our analysis of these Cdh1 interacting proteins revealed an 
important function for the negative regulation of APC activity at a specific time during 
the cell cycle.   
The interaction between Bmh1, Bmh2, and Cdh1 was found to be dependent on 
the presence of Acm1.  We found Bmh1 and Bmh2 levels to be constant throughout the 
cell cycle whereas Acm1 levels oscillate with the highest levels occurring in S phase.  
Hence, complex formation was restricted to the period of the cell cycle during which 
Acm1 was expressed.   
Cells were viable upon deleting Acm1 but exhibited a small perturbation during S 
phase when Acm1 levels are normally highest.  Levels of the APC substrate Clb2 were 
also slightly lower in acm1∆ cells under certain growth conditions.  Although these 
results suggested Acm1 played some role during S phase, the function of Acm1 was not 
clear until we discovered Acm1 was able to inhibit APCCdh1 activity both in vitro and in 
vivo.  The addition of Acm1 inhibited APCCdh1 mediated ubiquitination of Clb2 in an in 
vitro activity assay.  Overexpression of Acm1 in sic1∆ cells was lethal yielding the same 
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result as a cdh1∆ sic1∆ double mutant (112).  Overexpression of Acm1 also rescued 
lethality caused by overexpression of Cdh1.    
Although Cdh1 that is heavily phosphorylated cannot activate the APC, partially 
phosphorylated Cdh1 does have the ability to still activate the E3 ligase.  We found 
Acm1 to inhibit both nonphosphorylated and phosphorylated Cdh1 pointing towards an 
overlapping Cdh1 inhibition mechanism.  Therefore, Acm1 may be in place to complete 
Cdh1 inactivation when phosphorylation of the co-activator is not sufficient.   
We found Acm1 to also be phosphorylated in the cell.  Further investigation 
demonstrated that even though Acm1 is heavily phosphorylated, this modification is not 
required for functional inhibition.  Why then is Acm1 phosphorylated?  We observed a 
slight upshift in the band corresponding to Acm1 on a gel during cell cycle progression 
when Acm1 levels are highest.  A downshift in the Acm1 band is observed prior to its 
disappearance.  Additionally, our collaborator, Mark Hall has observed the instability of 
Acm1 CDK site phosphomutants mimicking nonphosphorylated Acm1 (Personal 
communication).  It appears phosphorylation of Acm1 may be involved somehow in its 
stability but at this time, we cannot say how.  Additional questions are then raised, like 
when and by what kinase is Acm1 phosphorylated?  What phosphatase removes 
phosphates from Acm1?  Further studies are needed to answer these important questions.   
We also found that Bmh1 and Bmh2 were not needed for APCCdh1 inhibition by 
Acm1 despite them forming a complex with Acm1.  The interaction between Bmh1 and 
Bmh2 was dependent on Acm1 phosphorylation.  Since nonphosphorylatable Acm1 is 
not stable, one cannot help but think one possible role for these proteins may be to aid in 
Acm1 stabilization.  Future directions include dissecting the role of the 14-3-3 proteins in 
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the complex with Cdh1 and Acm1 to determine if they are involved in protecting Acm1 
from premature degradation. 
When we first discovered Bmh1 and Bmh2 in complex with Acm1 and Cdh1, it 
was proposed that one possible role for the 14-3-3 proteins was in the relocalization of 
Cdh1.  Relocalization of Cdh1 from the nucleus to the cytoplasm was shown as another 
inhibitory mechanism to remove Cdh1 from the vicinity of APC when APCCdh1 activity is 
not needed (73).  Additionally, 14-3-3 proteins were known to be involved in the 
nuclear/cytoplasmic localization of cell cycle regulatory proteins (102).  Therefore, one 
hypothesis was that Bmh1 and Bmh2 played a similar role with Cdh1.  However, upon 
deleting Acm1, which mediates 14-3-3 binding to Cdh1, no difference in Cdh1 
localization between the nucleus and cytoplasm was observed (112).  Mark Hall’s group 
found that the complex did prevent Cdh1 localization to the bud neck in yeast (112).  The 
Cdh1 substrates Clb2 and Hsl1 have been shown to localize to the bud neck and these 
interactions are enhanced in the absence of Acm1 (112,116,117).  Since Bmh1 and Bmh2 
do not appear to play a direct role in APCCdh1 inhibition, these proteins may serve other 
important functions in vivo.  One possibility could be that Acm1/Bmh1/Bmh2 prevent 
Cdh1 from localizing to the bud neck when Cdh1 is in the cytoplasm.  However, further 
investigation is required to answer this question.   
We have also provided evidence that Acm1 acts as an APCCdh1 inhibitor by 
blocking substrate binding to the co-activator by mimicking an APC substrate.  Acm1 
contains APC substrate-like D boxes and a KEN box that is involved in substrate 
recognition and binding.  Mutation of these regions of Acm1 abolishes the interaction 
with Cdh1.  Additionally, Cdh1 contains WD-40 domains in its C-terminus that are 
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implicated in substrate binding.  We have shown Acm1 binds to the C-terminus of Cdh1.  
From gel filtration experiments, it appears Acm1 interacts with Cdh1 in a 1:1 ratio.  This 
suggests that Acm1 binds to a single site on Cdh1.  If Acm1 binds to a single Cdh1 site 
and the addition of Acm1 decreases substrate binding to Cdh1, then Acm1 must be a 
competitive inhibitor.   
Although Acm1 looks like an APC substrate, full length Acm1 does not appear to 
be ubiquitinated by the APC.  However, regions of Acm1 appear to prevent it from 
ubiquitination by the Cdh1-dependent APC.  Truncations of the N-terminus and C-
terminus of Acm1 were used in an in vitro ubiquitination assay revealing that both 
termini protect Acm1 from being processed as a substrate.  Without the intact N-terminus 
and C-terminus, Acm1 is ubiquitinated by APCCdh1.   Perhaps these regions block lysine 
residues from ubiquitination allowing Acm1 to act as a potent inhibitor by competing for 
substrate binding.  Since the SCF complex is the other main E3 ligase involved in cell 
cycle dependent proteolysis of proteins, it would be easy to suggest the SCF may play a 
role in the degradation of Acm1.  However, there is no precedent for SCF-mediated 
degradation of proteins in late Mitosis or that phosphorylation protects substrates from 
SCF targeting.  Furthermore, we do not know at this point if Acm1 is subjected to a 
ubiquitin-dependent proteolytic event.  Additional experimentation is needed to 
determine if Acm1 is degraded in a proteasome dependent manner and what machinery is 
potentially involved.   
The discovery of Acm1, Bmh1, and Bmh2 in complex with Cdh1 has provided us 
with additional insight into APC regulation.  APC regulation is of the utmost importance 
for maintaining strict cell cycle control thereby preventing genetic catastrophe.   Because 
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of this importance, multiple, overlapping mechanisms are in place to ensure complete 
inactivation of the APC for proper cell cycle progression.  The results illustrated in this 
dissertation may help in our global understanding of APC regulation leading to better 
comprehension of healthy cellular processes for the eventual prevention and treatment of 
diseases in the future.     
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